

March 31, 2026

**Subject: Pennsylvania Opioid Trust Solicitation for Research Support Services –
Development and Maintenance of Opioid Settlement Funds Reporting Tool**

Dear Academic Researchers at Institutions in Pennsylvania:

The Pennsylvania Opioid Misuse and Addiction Abatement Trust (“Trust”) is pleased to invite your institution to respond to the attached solicitation for professional services supporting the Trust’s ongoing reporting and compliance obligations related to certain opioid settlement funds paid into Pennsylvania. The Trust seeks qualified academic research partners to develop a secure, user-friendly online reporting tool, provide training and technical assistance, and prepare comprehensive reports to ensure effective monitoring of Participating Subdivisions’ expenditures. Please see the attached solicitation, which contains additional details.

All proposals in response to the solicitation must be received no later than **April 17, 2026**, and should be limited to five (5) pages. Responses should be directed to the Trust’s administrator via email at: administrator@paopioidtrust.org.

Please include in your proposal the overall total cost for a contract term of three years, with the possibility of two one-year renewals at the option of the Trust. If multiple academic institutions form a consortium or partnership, please submit a single combined proposal that includes the total projected costs for all parties involved.

Your proposal should clearly outline how your institution(s) will approach creating a reporting system substantially similar to the attached blank reporting tool (Tab A), as well as how you will meet other requirements listed in the solicitation, including collaboration with Trust staff, development of training materials, ongoing technical support, and preparation of requested reports for the Board of Trustees of the Trust. For reference, the Amended Trust Order governing these activities is also included (Tab B)

The Trust looks forward to your response and the opportunity to collaborate on this important initiative.

Sincerely,
The Pennsylvania Opioid Misuse and Addiction Abatement Trust

REPORTING AND MONITORING SERVICES FOR THE PENNSYLVANIA OPIOID MISUSE AND ADDICTION ABATEMENT TRUST

I. INTRODUCTION AND BACKGROUND

The Pennsylvania Opioid Misuse and Addiction Abatement Trust (“Trust”) was established by Order of the Pennsylvania Commonwealth Court on July 12, 2022, as amended on October 15, 2024 (the “Amended Trust Order”). A copy of the Amended Trust Order is attached at Tab A.

The Trust receives funds from certain national settlement agreements entered into by the Pennsylvania Office of Attorney General, on the one hand, and opioid manufacturers, distributors, and pharmacy companies, on the other hand. The Trust distributes those settlement funds to the Commonwealth of Pennsylvania, Counties, and Litigating Subdivisions (collectively, “Participating Subdivisions”)¹ and reviews reports on spending to ensure compliance with the Settlements.

Specifically, the Trust reviews certifications and reports from Participating Subdivisions on opioid settlement funds spent and committed and prepares an annual report to the Commonwealth Court. To fulfill these responsibilities, the Amended Trust Order requires:

Each County, Litigating Subdivision, and the Health Department of the City of the First Class shall submit a report to the Board of Trustees by March 15 beginning in the year 2023, showing the actual expenditures of such Trust Funds and the amount of Trust Funds received but not spent by the close of the previous calendar year or other time period designated by the Trust. The Trust may also require more frequent reporting, consistent with the provisions of this Order, as the Board of Trustees deems appropriate...

The Board of Trustees shall set the requirements of such reporting, with input from qualified academic researchers

Amended Trust Order, Section V(D)(11). In addition to the reporting requirement excerpted above, the Board of Trustees of the Trust (“Board”) unanimously approved a resolution to require each Participating Subdivision to submit a biannual report to the Board by September 15 of each year showing opioid settlement funds spent and committed from January 1 through June 30 of the same year. Thus, the Trust requires reports from Participating Subdivisions twice per year, with each reporting cycle covering a six-month period ending on the immediately prior December 31 or June 30, as the case may be.

¹ Unless otherwise defined herein, capitalized terms are as defined in the Amended Trust Order.

To assist in regularly collecting reports from each of the Participating Subdivisions, and as permitted by the Amended Trust Order, the Trust engaged a team of qualified academic researchers in 2023 to develop an online reporting tool through which Participating Subdivisions could make required reports to the Trust. A blank copy of the reporting tool is attached hereto at Tab B. The current contract with academic researchers will expire May 31, 2026.

II. SERVICES SOUGHT BY THE TRUST

The Trust now seeks the further assistance of qualified academic researchers to support the Trust's obligations to receive reports from Participating Subdivisions and to ensure compliance with the Settlements. Such services may include:

- Development of a secure and user-friendly online reporting tool system(s);
- Collaboration with the Trust's administrative staff;
- Development of training and reference materials for Participating Subdivisions on how to appropriately document and submit required reports according to a reporting schedule;
- Preparation and updating of comprehensive reports to the Board of Trustees of the Trust (the "Board");
- Technical assistance to Participating Subdivisions related to use of the reporting tool; and,
- Such other functions as the Trust's Board of Trustees may request.

The selected provider will collaborate closely with the Trust, the County Commissioners Association of Pennsylvania ("CCAP") and other key stakeholders to ensure effective reporting of the expenditure and/or commitment of opioid settlement funds.

TAB A

Participating Subdivision Information (REQUIRED)

As a Pennsylvania County and/or Litigating Subdivision (together, "Participating Subdivisions") receiving distributions from the Pennsylvania Opioid Misuse and Addiction Abatement Trust ("Trust"), please complete the Reporting Tool regarding your use of opioid settlement funds.

Important Notes:

Unless otherwise defined herein, capitalized terms are as defined in the July 12, 2022, Order of the Commonwealth Court of Pennsylvania creating the Trust, as amended and restated on October 15, 2024.

Resources to help you complete the Reporting Tool are included in the email with the link to your Participating Subdivision's report.

Your Participating Subdivision's previous reports to the Trust have been preloaded to minimize the need for repeated data entry. However, please review all fields in the survey below and provide updated information as needed.

This survey is for [SAMPLE PARTICIPATING SUBDIVISION].

According to our records, your Participating Subdivision has received \$[pmt_temp] from the Trust to date. Yes No

Is this accurate?

Please enter the amount your Participating Subdivision has received according to your records. _____
(Enter exact amount, including cents. Do NOT use commas (e.g., 123456.78).)

Reference Copy of Exhibit E
[Attachment: "Exhibit-E-List-of-Opioid-Remediation-Uses.pdf"]

Name of the person completing this survey. _____

Email address of the person completing this survey. _____

Phone number of the person completing this survey. _____

Remediation Programs

SECTION 1

Instructions for Reporting Remediation Program Information

The following questions will ask for details about the remediation program(s) your Participating Subdivision has implemented.

Please respond to the questions for each remediation program. Once you have answered all questions for a remediation program, you will be prompted to indicate whether there are additional remediation programs to report. If so, select 'Add another program' and complete the questions for each additional remediation program.

If a remediation program has one or more subparts (e.g., mini grants, subgrants, subprograms, etc.), please report each separately as its own remediation program.

If you are working with other Participating Subdivisions on a joint remediation program, please only report your Participating Subdivision's expenditures on the remediation program.

Please note: Be sure to read these questions carefully before responding.

Provide the name of the remediation program:

Please note: This field is locked for remediation programs that were previously reported.

Name of the organization managing the remediation program.

Name of the program manager.

Phone number of the program manager.

Email address of the program manager.

SECTION 2

Remediation Program Name: [SAMPLE REMEDIATION PROGRAM]

Is it anticipated that this remediation program will continue to be funded by opioid settlement funds following December 31, 2025? Yes No Don't know

Specify the month and year (MM/YYYY) in which opioid settlement funds were no longer used to fund this remediation program. _____

Provide an explanation for why the remediation program is no longer funded by opioid settlement funds (e.g., transitioned to other funding sources, deemed ineffective, intended as a one-time initiative, etc.). _____

Were any funds spent during the Reporting Period (July 1, 2025, to December 31, 2025) for this remediation program? Yes No

What is the amount of opioid settlement funds spent on this remediation program during the Reporting Period (July 1, 2025, to December 31, 2025)?

Please note: "Spent" refers to opioid settlement funds that have been paid out during the Reporting Period specifically for the remediation program.

(Enter exact amount, including cents. Do NOT use commas (e.g., 123456.78))

As of December 31, 2025, were there any outstanding committed funds for this remediation program, including commitments made during this Reporting Period and/or carried over from prior reporting periods? Yes No

As of December 31, 2025, what is the amount of outstanding committed opioid settlement funds for this remediation program, including commitments made during this Reporting Period (July 1, 2025, to December 31, 2025) and/or carried over from prior reporting periods?

Please note: "Committed" refers to opioid settlement funds that have been designated or allocated for the remediation program through a signed or awarded contract or memorandum of understanding but have not yet been spent. Do NOT include spent funds in this amount.

(Enter exact amount, including cents. Do NOT use commas (e.g., 123456.78). Do NOT include spent funds in this amount.)

Please confirm that you understand that newly reported remediation programs with no spent or committed opioid settlement funds will be removed from [munic_resp]'s record after the submission deadline and will not be reviewed by the Trust.

I understand.

This program must be reentered in a future reporting cycle if funds are spent and/or committed during the applicable reporting period.

Are any other sources of funding, besides opioid settlement funds, being used to support this remediation program?

Yes
 No

What other source(s) of funding are being used?

Check all that apply.

- Organization
- Municipal
- County
- State
- Federal
- Other

SECTION 3

Remediation Program Name: [SAMPLE REMEDIATION PROGRAM]

Provide a narrative description to help the Trust and the public understand this remediation program. Some examples of helpful information to include:

- Service(s) provided
- Population(s) served
- Current or projected goals, outcomes, or key performance indicators
- Description of whether remediation program is evidence-based or evidence-informed
- Any notable partnerships, innovations, or unique aspects Please note: Writing "see attached" is NOT sufficient. The Trust may require you to revise your program description to ensure it fully addresses the question's requirements.

If you need more space, upload the additional information as an attachment.

If this remediation program continues to be funded by opioid settlement funds, explain why additional funds are being spent and/or committed during this Reporting Period (e.g., ongoing program needs, unanticipated costs, program expansion or enhancement, etc.).

Does this remediation program address opioid use disorder (OUD) and any co-occurring substance use disorders (SUDs) and/or mental health (MH) conditions? Yes No

For example, does this remediation program treat individuals with OUD and alcohol use disorder (AUD)?

How does your remediation program address OUD while also addressing co-occurring SUDs/MH conditions?

Attach any supporting documentation not previously submitted (e.g., detailed budgets, program literature, photos, flyers, curriculum, relevant sections of grant applications, etc.).

Are you collaborating with any other Participating Subdivisions (i.e., entities that receive distributions from the Trust) on this remediation program? Yes No

List the other Participating Subdivision(s) you are collaborating with on this remediation program.

Was this remediation program already in place prior to receiving distributions from the Trust? Yes No

SECTION 4

Remediation Program Name: [SAMPLE REMEDIATION PROGRAM]

Where does this remediation program fall within Exhibit E?

- Schedule A
- Schedule B

First select the applicable schedule, then select the sections and subsections within that schedule that apply.

Please note: You are limited to three (3) selections for sections and subsections.

Please list the specific Exhibit E Schedule A and/or B section(s) and subsection(s) you believe your Participating Subdivision's remediation program falls under. You may choose a maximum of 3 sections and subsections. The full list of section and subsection options have been cropped from this blank survey for easier viewing/printing, but are available on the online Reporting Tool.

SECTION 5: ADDITIONAL INFORMATION FOR PUBLIC REPORTING**Remediation Program Name:** [SAMPLE REMEDIATION PROGRAM]

The questions below are solely to provide additional information and insight to the public about remediation programs funded by opioid settlement funds.

Your response here will not be used by the Trust to determine the compliance of any specific remediation program with Exhibit E.

You may refer to the PDF linked below for additional information that could help answer these questions.

[Attachment: "Taxonomy explainer.pdf"]

Please select the category that best represents the primary aim of the reported remediation program.

You may select multiple categories to represent shared aims of the remediation program.

- Prevention
- Treatment - Medications for Opioid Use Disorder
- Treatment - Other
- Harm Reduction - Naloxone
- Harm Reduction - Other
- Family-Centered Support Programs
- Safe Disposal
- Recovery Support
- Stigma Reduction
- Data Collection/Research
- Infrastructure Support

Please select the population that is primarily served/benefited by the reported remediation program.
You may select multiple population categories if needed.

- Individuals who use opioids
- Individuals seeking Treatment for Opioid Use Disorder
- Individuals in recovery of opioid use disorder
- Family members of those who use opioids
- Community members impacted by the opioid epidemic
- Justice-involved Individuals
- Pregnant Women
- Infants (those under 6 months)
- Adolescents (those under 18)
- Adults (those aged 18+)
- Elderly (65+)
- Healthcare Personnel
- Substance Use Treatment Personnel
- Mental Health Treatment Personnel
- Law Enforcement Personnel
- First Responders/EMT
- The General Public
- Other:

Please describe the 'other' population.

Non-Opioid Remediation Use Reporting (REQUIRED)

Under the applicable national opioid settlement agreements, Participating Subdivisions that have received opioid settlement funds are required to report any funds spent on purposes other than Opioid Remediation to the National Administrators every six (6) months. The Trust will submit this information in the aggregate on behalf of all Pennsylvania Participating Subdivisions. This reporting requirement is outlined in the following sections of each of these national opioid settlement agreements: Distributor Settlement Agreement (Section V.B.2); Janssen Settlement Agreement (Section VI.B.2); Allergan Public Global Opioid Settlement (Section VIII.C); Teva Global Opioid Settlement Agreement (Section VIII.C); Walmart Settlement Agreement (Section V.B); CVS Settlement Agreement (Section V.B); and Walgreens Settlement Agreement (Section V.B).

Please note: The national opioid settlement agreements define "Opioid Remediation" as:

"Care, treatment, and other programs and expenditures (including reimbursement for past such programs or expenditures [including amounts paid to any governmental entities for past expenditures or programs] . . .) designed to (1) address the misuse and abuse of opioid products, (2) treat or mitigate opioid use or related disorders, or (3) mitigate other alleged effects of, including on those injured as a result of, the opioid epidemic. Qualifying expenditures may include reasonable related administrative expenses."

Opioid Remediation does not include funds used to pay (or reimburse for) attorneys' fees, investigation costs, litigation costs, or costs related to the operation and enforcement of the national opioid settlement agreements; these expenditures must be reported to the Trust in this survey.

All reports will be publicly available pursuant to the above-referenced provisions of the applicable national opioid settlement agreements.

Please note that reports from the Trust to the National Administrators will continue to be due at six (6)-month intervals (e.g., September 30, 2026; March 31, 2027; etc.) for the remaining terms of the respective national opioid settlements. Subsequent reports will cover new spending, if any, during the immediately preceding six (6)-month period (January 1 to June 30; and July 1 to December 31). If your Participating Subdivision obtains new information about spending from a prior reporting period after a deadline has passed, please notify the Trust Administrator as soon as possible.

Did your Participating Subdivision have any non-opioid remediation expenditures during the Reporting Period (July 1, 2025, to December 31, 2025)?

- Yes
 No

How many separate non-opioid remediation expenditures did you have during the Reporting Period (July 1, 2025, to December 31, 2025)?

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10

For each expenditure, you will be asked to provide the recipient, amount, and a description.

Name the recipient of this non-opioid remediation expense.

Enter the amount for this non-opioid remediation expense.

_____ (Enter exact amount, including cents. Do NOT use commas (e.g., 123456.78))

Provide a brief description of the purpose of this non-opioid remediation expense.

Summary (REQUIRED)

According to our records, your Participating Subdivision has received to date = \$[_____]

You specified an alternate amount received = \$[_____].

Opioid Remediation Reporting Summary

The calculated total spent on all remediation programs in this Reporting Period = \$[_____]

If you disagree with the calculation above, please first review your reported expenditures for each remediation program in the Reporting Tool. If the calculation is still incorrect, specify the correct total amount spent.

The calculated total committed to all remediation programs = \$[_____]

If you disagree with the calculation above, please first review your reported expenditures for each remediation program in the Reporting Tool. If the calculation is still incorrect, specify the correct total amount committed.

Non-Opioid Remediation Reporting Summary

The calculated total spent on all non-opioid remediation use in this Reporting Period = \$[non_opioid_summary]

If you disagree with the calculation above, please first review your reported non-opioid remediation expenditures in the Reporting Tool. If the calculation is still incorrect, specify the correct total amount spent on non-opioid remediation uses.

Please refer to your Participating Subdivision's most recent Notification of Approval and/or Additional Information Required for the most up-to-date amounts remaining to be spent and/or committed by the applicable deadline(s).

Submission status attestation

- I am confirming my submission is final and ready to be reviewed by the Trust.
- My submission is not final and is not ready to be reviewed by the Trust.

TAB B

IN THE COMMONWEALTH COURT OF PENNSYLVANIA

COMMONWEALTH OF
PENNSYLVANIA, by Attorney
General, JOSH SHAPIRO,

Petitioner,

v.

AMERISOURCEBERGEN
CORPORATION; MCKESSON
CORPORATION; and CARDINAL
HEALTH, INC.,

Respondents.

244 MD 2022

COMMONWEALTH OF
PENNSYLVANIA, by Attorney
General, JOSH SHAPIRO,

Petitioner,

v.

JOHNSON & JOHNSON; JANSSEN
PHARMACEUTICALS, INC.; ORTHO-
MCNEIL-JANSSEN
PHARMACEUTICALS, INC.; and
JANSSEN PHARMACEUTICA, INC.,

Respondents.

243 MD 2022

**FIRST AMENDED AND RESTATED
PENNSYLVANIA OPIOID MISUSE AND ADDICTION
ABATEMENT TRUST**

WHEREAS, the Pennsylvania Opioid Misuse and Addiction
Abatement Trust (“Trust”) established under the Court’s Order dated July

12, 2022 was created for the purpose of distributing Trust funds obtained by the Commonwealth and its subdivisions under (a) the Distributors Settlement Agreement and the J&J Settlement Agreement, both as defined below, and (b) Other Settlements, as defined below; and

WHEREAS, the Commonwealth and certain of its subdivisions have since entered into settlement agreements with Teva, Allergan, CVS, Walgreens, and/or Walmart; and

WHEREAS, the Trust is hereby amended and restated in its entirety as set forth herein, with certain changes made to address the distribution of funds to be received pursuant to the Teva Settlement Agreement, the Allergan Settlement Agreement, the CVS Settlement Agreement, the Walgreens Settlement Agreement, and the Walmart Settlement Agreement, all as defined below.

I. INTRODUCTION

- A. On April 18, 2022, the Commonwealth of Pennsylvania (“Commonwealth”) filed a Complaint naming McKesson Corporation, Cardinal Health, Inc. and AmerisourceBergen Corporation (“Distributors”) as Respondents, alleging their actions furthered the improper distribution of prescription

opioid drugs made and marketed by pharmaceutical manufacturers (the “Commonwealth’s Distributor Claims”).

- B. The Complaint is docketed at 244 M.D. 2022.
- C. The Distributors each deny that they have engaged in any wrongdoing.
- D. On April 18, 2022, the Commonwealth filed a Complaint naming Johnson and Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc. (collectively “J&J”) as Respondents, alleging that J&J had violated various Commonwealth laws through its manufacture, sale and promotion of prescription opioid products (the “Commonwealth’s J&J Claims”).
- E. The Complaint against J&J is docketed at 243 M.D. 2022.
- F. J&J denies that it has engaged in any wrongdoing.
- G. On April 25, 2022, the Commonwealth, the Distributors and J&J filed a stipulated application to consolidate the actions in Commonwealth v. AmerisourceBergen, Docket No. 244 M.D. 2022 and Commonwealth v. J&J, Docket 243 M.D. 2022.

- H. On April 29, 2022, the Commonwealth and the Distributors filed a settlement of the Commonwealth’s Distributor Claims in the form of a Final Consent Judgment.
- I. On April 29, 2022, the Commonwealth and J&J filed a settlement of the Commonwealth’s J&J Claims in the form of a Final Consent Judgment.
- J. The Distributors Settlement Agreement and J&J Settlement Agreement (the “Wave 1 Settlements” as referenced in Section III.T.) will deliver up to \$1,070,609,642 to the Commonwealth over as many as 18 years with payments to be made as described in Paragraph IV. C-D of the Distributors Settlement Agreement and Paragraphs V. B1 and V. B8 of the J&J Settlement Agreement.
- K. On February 16, 2024, the Commonwealth filed a Complaint naming Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., and Cephalon, Inc. (collectively “Teva”) as Respondents, alleging that Teva had violated various Commonwealth laws through its manufacture, sale and promotion of prescription opioid products (the “Commonwealth’s Teva Claims”).

- L. The Complaint against Teva is docketed at 59 M.D. 2024.
- M. Teva denies that it has engaged in any wrongdoing.
- N. On February 16, 2024, the Commonwealth filed a Complaint naming Allergan Limited, Allergan Finance, LLC, Watson Laboratories, Inc., Actavis Pharma, Inc., Actavis LLC, (collectively “Allergan”) as Respondents, alleging that Allergan had violated various Commonwealth laws through its manufacture, sale and promotion of prescription opioid products (the “Commonwealth’s Allergan Claims”).
- O. The Complaint against Allergan is docketed at 59 M.D. 2024.
- P. Allergan denies that it has engaged in any wrongdoing.
- Q. On February 15, 2024, the Commonwealth filed a Complaint naming Walgreen, Co (“Walgreens”) as Respondent, alleging that Walgreens had violated various Commonwealth laws through its sale, distribution and promotion of prescription opioid products (the “Commonwealth’s Walgreens Claims”).
- R. The Complaint against Walgreens is docketed at 58 M.D. 2024.
- S. Walgreens denies that it has engaged in any wrongdoing.
- T. On February 15, 2024, the Commonwealth filed a Complaint naming CVS Pharmacy, Inc. (“CVS”) as Respondent, alleging

that CVS had violated various Commonwealth laws through its sale, distribution and promotion of prescription opioid products (the “Commonwealth’s CVS Claims”).

- U. The Complaint against CVS is docketed at 58 M.D. 2024.
- V. CVS denies that it has engaged in any wrongdoing.
- W. On February 15, 2024, the Commonwealth filed a Complaint naming Walmart Inc., (“Walmart”) as Respondents, alleging that Walmart had violated various Commonwealth laws through its sale, distribution and promotion of prescription opioid products (the “Commonwealth’s Walmart Claims”).
- X. The Complaint against Walmart is docketed at 58 M.D. 2024.
- Y. Walmart denies that it has engaged in any wrongdoing.
- Z. On March 1, 2024, the Commonwealth and Teva filed a settlement of the Commonwealth’s Teva Claims in the form of a Final Consent Judgment.
- AA. On March 1, 2024, the Commonwealth and Allergan filed a settlement of the Commonwealth’s Allergan Claims in the form of a Final Consent Judgment.

- BB. On February 21, 2024, the Commonwealth and Walgreens filed a settlement of the Commonwealth's Walgreens Claims in the form of a Final Consent Judgment.
- CC. On February 21, 2024, the Commonwealth and filed a settlement of the Commonwealth's CVS Claims in the form of a Final Consent Judgment.
- DD. On March 1, 2024, the Commonwealth and Walmart filed a settlement of the Commonwealth's Walmart Claims in the form of a Final Consent Judgment.
- EE. On March 6, 2024, the Commonwealth Court entered Teva and Allergan's Consent Judgments as Orders of the Court.
- FF. On April 5, 2024, the Commonwealth Court entered Walgreens, CVS, and Walmart's Consent Judgments as Orders of the Court.
- GG. The Teva Settlement Agreement, Allergan Settlement Agreement, Walgreens Settlement Agreement, CVS Settlement Agreement, and Walmart Settlement Agreement (the "Wave 2 Settlements" as referenced in Section III.U.) will deliver up to \$773,387,187.72 to the Commonwealth over as many as 15 years with payments to be made as described in Paragraph VII.

B of the Teva and Allergan Settlement Agreements, Paragraphs IV.B-C of the Walgreens Settlement Agreement, Paragraphs IV.B-C of the CVS Settlement Agreement, and Paragraph IV.B of the Walmart Settlement Agreement.

Upon a motion from the Commonwealth, the Court orders the following:

II. ORDER

A. The Pennsylvania Opioid Misuse and Addiction Abatement Trust.

1. As indicated, by Court Order dated July 12, 2022, the Trust was created, which is hereby amended and restated in its entirety. All payments shall be made by the Distributors, J&J, Teva, Allergan, Walgreens, CVS, and Walmart to the Trust as amended and restated, pursuant to the terms of the Wave 1 Settlements and the Wave 2 Settlements. After the payment by the Trust of Attorneys' Fees and Expenses as described in Section IX of this Order and in Exhibits 4 and 8 attached hereto, into a fund to be maintained in the Delaware County Court of Common Pleas, the remaining Trust Funds shall be

divided into three accounts upon distribution: The Commonwealth Account, the County Abatement Account, and the Litigating Subdivision Account.

- a. The Commonwealth Account¹ shall consist of Fifteen (15) % of the Trust Funds to be distributed and shall be paid to the Commonwealth for deposit to the Opioid Settlement Restricted Account as established by 72 P.S. § 1792-A.1.
- b. The County Abatement Account shall consist of Seventy (70) % of the Trust Funds to be distributed and shall be paid to Counties and other County Subdivisions in the manner described in the Allocation Section at ¶VII(A) below.
- c. The Litigating Subdivision Account shall consist of Fifteen (15) % of the Trust Funds to be distributed and shall be paid directly to the

¹ Pursuant to the Commonwealth's Side Letters with Teva, Allergan, and Walmart, the Commonwealth Account's funds from these settlements are in escrow. There will be no distribution to the Commonwealth Account from the Teva, Allergan, and Walmart Settlements unless the Supreme Court of Pennsylvania rules in favor of the Attorney General in its litigation against the District Attorneys of Philadelphia and Allegheny County.

Litigating Subdivisions in the manner described in the Allocation Section at ¶VII(B) below.

B. Methodology and Requirements. This Order sets forth the methodology and requirements for allocation and payment of Trust Funds achieved as the result of Pennsylvania’s Opioid Litigation, as defined below. Every Participating Subdivision that agrees to participate in one or more of the Settlements and accept the Trust Funds described herein shall be subject to the jurisdiction of this Court for compliance and enforcement of this Order and also have standing to petition this Court for enforcement of this Order and payment of the Trust Funds allocated to it. No Participating Subdivision may challenge another Participating Subdivision’s use of funds, but Participating Subdivisions in the same geographic region are encouraged to coordinate their use of Trust Funds allocated by this Order.

III. DEFINITIONS

- A. **OAG** – The Pennsylvania Office of Attorney General.
- B. **Commonwealth.** The Commonwealth of Pennsylvania.

- C. **Companies** – collectively means McKesson Corporation, Cardinal Health, Inc., Cencora, Inc. f/k/a AmerisourceBergen Corporation, J&J, Teva, Allergan, CVS, Walgreens, and Walmart.
- D. **Board of Trustees** – Trustees appointed pursuant to this Order to manage and direct the Trust.
- E. **Covered conduct** – means “Covered Conduct” as defined in the: Distributors Settlement Agreement at Paragraph I.O.; J&J Settlement Agreement at Paragraph I.16.; Teva Settlement Agreement at Paragraph I.21.; Allergan Settlement Agreement at Paragraph I.20.; Walgreens Settlement Agreement at Paragraph I.S.; CVS Settlement Agreement at Paragraph I.P.; and Walmart Settlement Agreement at Paragraph I.P.
- F. **Counties**—Subdivisions, as enumerated and classified in 16 P.S. § 201 to 211.
- G. **County Subdivisions** – All political subdivisions within a given county, including, but not limited to, cities, townships, boroughs, school districts, and municipal authorities.
- H. **Intrastate Allocation Formula.** The formula for distributing funds from the County Abatement Fund contained in Exhibit 1.

- I. **Litigating Subdivisions.** For Wave 1 Defendants, Counties, County Subdivisions, and District Attorneys that had existing litigation against the Wave 1 Defendants as of July 21, 2021, and for Wave 2 Defendants, Counties, County Subdivisions, and District Attorneys that had existing litigation against the Wave 2 Defendants as of December 9, 2022. For purposes of Teva and Allergan, any County, County Subdivision, or District Attorney that had existing litigation against Teva will be treated as having litigation against Allergan, although those Subdivisions that did not have litigation against Allergan shall be subject to the Allocation Adjustment in Exhibit 7. For the purposes of Walgreens, CVS, and Walmart, any County, County Subdivision, or District Attorney that had existing litigation against one of Walgreens, CVS, and Walmart will be treated as having litigation against all three.
- J. **Non-Participating Subdivisions.** Counties and County Subdivisions with populations greater than 10,000 that have not chosen to participate in these Settlements.
- K. **Participating Subdivisions.** Counties, District Attorneys and County Subdivisions of more than 10,000 in population as

established by the 2019 population estimate of the U.S. Bureau of Census that have agreed to participate in these Settlements. The Participating Subdivisions for the Wave 1 Settlements are identified in Exhibit 5 to this Order. The Participating Subdivisions for each of the Wave 2 Settlements are identified in Exhibit 6 to this Order.

- L. **Pennsylvania’s Opioid Litigation.** The Coordinated Opioid Proceedings (CV-2017-08095) pending in the Delaware County Court of Common Pleas before the Hon. Barry C. Dozor, and any proceedings initiated by Litigating Subdivisions pending in *In re National Prescription Opiate Litig.* MDL No. 2804 (N.D. Ohio), pending before the Hon. Daniel Polster.
- M. **Population.** Whenever this Order refers to population, it refers to the 2019 estimate of the United States population by the U.S. Bureau of Census, except for purposes of calculating the Litigating Subdivisions’ shares, a process that uses 2020 Census figures.
- N. **Settlements.** The settlements set forth in the Distributors Settlement Agreement, dated July 21, 2021, among the settling states, settling distributors and participating subdivisions; the

J&J Settlement Agreement, dated July 21, 2021, among the settling states, participating subdivisions and J&J; the Teva Settlement Agreement, dated February 8, 2023, among the settling states, participating subdivisions and Teva; the Allergan Settlement Agreement, dated February 8, 2023, among the settling states, participating subdivisions and Allergan; the Walgreens Settlement Agreement, dated December 9, 2022, among the settling states, participating subdivisions and Walgreens; the CVS Settlement Agreement, dated February 3, 2023, among the settling states, participating subdivisions and CVS; and the Walmart Settlement Agreement, dated February 7, 2023, among the settling states, participating subdivisions and Walmart, for Covered Conduct.

- O. **Other Settlement(s).** Any of the following pertaining to liability arising from the marketing, manufacturing, sale, promotion, distribution, prescribing or dispensing of opioids shall fall within the purview of this Order: a future settlement agreement entered into by OAG together with subdivisions, and District Attorneys, and any monetary amounts awarded as a result of such litigation by OAG together with subdivisions, and

District Attorneys; or Court ordered distributions pursuant to a United States Bankruptcy Court approved plan for claims of the Commonwealth, its subdivisions and District Attorneys.

P. **Single-County Authorities (“SCAs”).** The agency designated under 4 Pa. Code §§ 254.1 to 254.20 to plan and coordinate drug and alcohol prevention, intervention and treatment services for a geographic area which may consist of one or more Counties and to administer the provisions of such services funded through the agency. Some Counties have agreements to coordinate the operation of a Single County Authority with other Counties either by having one County’s SCA act for multiple Counties or by retaining a vendor to perform such function for multiple Counties. In either event, such organizations shall be considered an SCA for purposes of this Order.

Q. **Trust** – Pennsylvania Opioid Misuse and Addiction Abatement Trust, as amended and restated. For the avoidance of doubt, the Trust is not a Commonwealth Agency, a local agency, a judicial agency, or a legislative agency.

- R. **Trust Funds** – Funds received by the Trust from Distributors, J&J, Teva, Allergan, Walgreens, CVS, and Walmart to the Trust as amended and restated, pursuant to the terms of the Wave 1 Settlements and the Wave 2 Settlements and any Other Settlement(s).
- S. **Settling Defendants** – All Companies, as well as any entity that made a Court ordered distribution to the Trust pursuant to a United States Bankruptcy Court approved plan.
- T. **Wave 1 Settlements** – collectively means the settlements with Distributors and J&J.
- U. **Wave 2 Settlements** – collectively means the settlements with Teva, Allergan, Walgreens, CVS, and Walmart.

IV. PARTIES TO THIS ORDER

- A. The Commonwealth, by and through the OAG.
- B. Participating Subdivisions.

V. PENNSYLVANIA OPIOID MISUSE AND ADDICTION ABATEMENT TRUST (TRUST)

- A. **Purpose.** The Trust shall have as its purpose to distribute Trust Funds obtained by the Commonwealth and its subdivisions

from the Wave 1 and Wave 2 Settlements and Other Settlements. The Trust shall receive Trust Funds, hold such funds until payment, and then disburse such funds pursuant to the terms and conditions set forth herein.

B. Disposition of Trust Funds. The Trust Funds obtained and ultimately paid by the Trust shall be distributed to the Commonwealth and its Participating Subdivisions only for the purposes set forth in Exhibit E to the Settlements and the Trust shall review expenditures by the Commonwealth and Participating Subdivisions which receive Trust Funds to ensure that such spending was consistent with Exhibit E. Exhibit E is incorporated into this Order by reference and all spending of Trust Funds allocated by this Order shall be consistent with the requirements of Exhibit E. The Trust shall also receive and distribute funds from Other Settlements pursuant to the terms of those Other Settlements.

C. Governance. The Trust shall be governed by a Board of Trustees consisting of the following 13 members:

1. Chairperson, appointed by the Governor. The Chairperson shall be non-voting, except in cases of a tie.

The Chairperson may not be an individual qualified to serve under any category of state-level members. The Chairperson shall serve at the pleasure of the Governor.

2. A secretary of one of the Commonwealth's health and human services agencies, as appointed by the Governor. The secretary may appoint a designee, who is an employee of the respective agency.
3. Four Legislative Member Trustees, with one Trustee appointed by each:
 - a. The Speaker of the House;
 - b. The Minority Leader of the House;
 - c. The President Pro Tempore of the Senate; and
 - d. The Senate Minority Leader.
4. Seven Regional Trustees appointed by the following County or City Officials:
 - a. Mayor of the City of First Class;
 - b. The County Executive of the County Second Class;
 - c. County Commissioners or County Executives of the Counties in the Capital Region, defined as

including the following 16 counties: Adams, Berks, Centre, Cumberland, Dauphin, Fulton, Franklin, Huntingdon, Juniata, Lancaster, Lebanon, Mifflin, Perry, Snyder, Union, and York;

- d. The County Commissioners or County Executives of the Northeastern Pennsylvania region, defined as including the following 18 counties: Bradford, Carbon, Clinton, Columbia, Lackawanna, Luzerne, Lycoming, Monroe, Montour, Northumberland, Pike, Potter, Schuylkill, Sullivan, Susquehanna, Tioga, Wayne, and Wyoming;
- e. The County Commissioners or County Executives of the Southeastern Pennsylvania region, defined as including the following 6 counties: Bucks, Chester, Delaware, Lehigh, Montgomery, and Northampton;
- f. The County Commissioners or County Executives of the Northwestern Pennsylvania, defined as including the following 13 counties: Armstrong, Cameron, Clarion, Clearfield, Crawford, Elk, Erie,

Forest, Jefferson, Mercer, McKean, Venango, and Warren;

- g. The County Commissioners or County Executives of the Southwestern Pennsylvania, defined as including the following 12 counties: Beaver, Bedford, Blair, Butler, Cambria, Fayette, Greene, Indiana, Lawrence, Somerset, Washington, and Westmoreland.

5. Appointment of Trustees

- a. The Chairperson shall be appointed by the Governor.
- b. The Trustee appointed by the Mayor of the City of the First Class shall be confirmed by a majority vote by the City Council of the City of the First Class.
- c. The Trustee appointed by the County Executive of the County of the Second Class shall be appointed by the County Executive.

- d. A Trustee appointed by the County Commissioners of the Five County Regions, under ¶(V)(B)(4)(c)-(g) shall be selected by a majority of votes from each County within each respective region. Each County shall have one vote for selecting the Trustee for its respective region. In the event of a tie vote among the Counties in a region, the Chairperson shall select a Trustee from the pool of candidates from each region that received the highest number of equal votes. At the request of any County, the County Commissioners Association of Pennsylvania may provide assistance to facilitate the nomination and election of Trustees.
- e. Subsequent Appointments to the Board of Trustees from the five regions shall be held in two-year intervals, beginning in 2025. The County with the largest population in each region shall be responsible for collecting nominations from each County and preparing and distributing ballots in

enough time to seat new Trustees, by July 1, 2025, if existing Trustees are not reelected. Counties in a region can retain an existing Trustee by unanimous consent without holding a new nomination and balloting process as long as the Trustee has not exceeded maximum term as described in ¶V(B)(8)(b).

6. Qualifications of Trustees

Counties are encouraged to designate Trustees from one or more of the following professional classifications.

- a. A County Commissioner, member of County Council or County Executive.
- b. SCA administrator or County Health Commissioner.
- c. Physician with specialized practice and training in the treatment of substance use disorder.
- d. Nurse with specialized practice and training the treatment of substance use.

- e. Certified peer support substance use disorder treatment provider/specialist.
- f. Licensed pharmacist.
- g. Emergency medical services provider.
- h. Re-entry specialist/service provider.
- i. Individual in recovery from substance use disorder.
- j. Parent or guardian of someone who has had opioid use disorder.
- k. A researcher with expertise in substance use from a college or university in the Commonwealth.

7. Residency:

- a. To qualify as a Regional Representative Trustee, an individual must reside in or have a principal place of business qualifying the individual for service on the Board of Trustees located in that region.

8. Terms:

- a. Legislative member Trustees shall serve terms not exceeding two years, which shall expire at the

conclusion of each legislative session. Legislative member Trustees may be re-appointed, with no limit on the number of times they may be re-appointed.

- b. Regional Representative Trustees, except for Trustees appointed in 2022, shall serve two-year terms and may be appointed three times consecutively. The term for Trustees appointed in 2022 shall continue until July 1, 2025. No individual shall serve more than ten years during the individual's lifetime as a Regional Trustee.
- c. A secretary of one of the Commonwealth's health and human services agencies or such secretary's designee shall serve a term of no more than eight years and may be replaced by the secretary at any time.
- d. In the event of a resignation or removal of a Trustee, the person appointing the Trustee shall appoint a replacement.

9. **Compensation:** Trustees shall serve as volunteers and shall receive no compensation for serving on the Board of Trustees. They shall be entitled to reasonable travel, lodging and subsistence expenses when attending meetings of the Board of Trustees, which shall be paid from the monies allocated for the Trust's management set forth in ¶IV(C)(9).

D. Operations

1. The Board of Trustees shall meet as frequently as the Chairperson determines is necessary to complete its work. During such meetings, the Trustees shall appoint a financial institution licensed by the United States Office of the Comptroller of the Currency to invest all funds received only in securities fully guaranteed by the Government of the United States of America and which shall have a maturity date of no more than one year.
2. Except for the year 2022, by September 1 of each year, The Board of Trustees shall notify each County and each Litigating Subdivision of the amounts each will receive

out of the County Abatement and Litigating Subdivision Accounts.

3. Except for the year 2022, by November 15 of each year, in order for Trust Funds to be paid from the County Abatement Account, each County, the Health Department of a City of the First Class shall submit to the Trust the certification substantially in the form attached as Exhibit 2 and list the payees and respective addresses to which the County Abatement Check shall be sent. Multiple Counties and the Health Department of the City of the First Class, County Subdivisions, and District Attorneys may file joint certifications for some or all of the Trust Funds allocated to them. A joint certification shall designate the amount to be paid out of the joint applicants' allocation and the name and address of the payee.

4. Except for the year 2022, by November 15 of each year, in order for Trust Funds to be distributed from the Litigating Subdivision Account, each Litigating Subdivision shall submit to the Trust the certification

substantially in the form attached as Exhibit 3 and list the payees and respective addresses to which the Litigating Subdivision Check shall be sent in accordance with ¶(VII)(B). Multiple Litigating Subdivisions may file joint certifications for some or all of the Trust Funds allocated to them.

5. In the year 2022, certifications shall be filed consistent with the terms of subparagraphs 2, 3, and 4 above within 60 days of entry of this Order.
6. Except for the year 2022, the Board of Trustees shall distribute the Trust Funds it holds in trust less the minimum amount needed to maintain its account for holding such Trust Funds on or before June 15 of each year for funds to be distributed to the Commonwealth Account², and on or before December 15 of each year for Trust Funds to be distributed from the County Abatement and Litigating Subdivision Accounts.

² Pursuant to the Commonwealth's Side Letters with Teva, Allergan, and Walmart, the Commonwealth Account's funds from these settlements are in escrow. There will be no distribution to the Commonwealth Account from the Teva, Allergan, and Walmart Settlements unless the Supreme Court of Pennsylvania rules in favor of the Attorney General in its litigation against the District Attorneys of Philadelphia and Allegheny County.

7. In the year 2022, the Trust shall distribute the Trust Funds it receives within 60 days of receipt in accordance with the allocations under ¶II(A)(1).
8. The Trust Funds designated to the Commonwealth Account shall be distributed from the Trust to the Commonwealth's Opioid Settlement Restricted Account.
9. The Board of Trustees may use up to 1% of the Trust Funds to retain such persons or firms to manage the investment and distributions.
10. All Trust Funds, except for those from the Walmart Settlement, must be spent within 18 months of receipt by the recipient unless a Participating Subdivision elects to use such funds for a multi-year capital project in accordance with Exhibit E of Settlements. Funds from the Walmart settlement must be spent within 42 months of receipt by the recipient unless a Subdivision elects to use such funds for a multi-year capital project in accordance with Exhibit E.
11. Each County, Litigating Subdivision, and the Health Department of the City of the First Class shall submit a

report to the Board of Trustees by March 15 beginning in the year 2023, showing the actual expenditures of such Trust Funds and the amount of Trust Funds received but not spent by the close of the previous calendar year or other time period designated by the Trust. The Trust may also require more frequent reporting, consistent with the provisions of this Order, as the Board of Trustees deems appropriate. Trust Funds should be spent equitably across the County in a way that most effectively abates the effects of the Opioid misuse and addiction within the judgment of the County Commissioners, County Executive and County Council. The Board of Trustees shall set the requirements of such reporting, with input from qualified academic researchers.

12. By September 30 of each year until the Trust is dissolved pursuant to paragraph VII.A., each Commonwealth agency that received an appropriation from the Commonwealth's Opioid Settlement Restricted Account ("OSRA") of monies received from the Commonwealth Account pursuant to paragraph II.A.1.a. shall report the

following information to the Trust for the Commonwealth's fiscal year that ended on the June 30th immediately preceding the date of the report: the amount appropriated to the agency from the OSRA; the amount of such appropriation that was expended by the agency during that fiscal year in compliance with Exhibit E; and, the amount of such appropriation that remained unexpended by June 30. The Trust may also request at other times, within reason and in writing, a report covering these same data points from each Commonwealth agency that received an appropriation from the OSRA of monies received from the Commonwealth Account, and the agency shall provide a report to the Trust within 30 days of the date of the Trust's request that covers the period between the first day of the Commonwealth fiscal year in which the request is received through the date on which the agency received the Trust's request.

13. A Quorum of seven Trustees shall be necessary to conduct business of the Board of Trustees.

14. The Board of Trustees may adopt any other operating procedures it deems fit, so long as such procedures are consistent with this Order and all applicable laws.

VI. RESPONSIBILITIES OF THE TRUST

- A. The Trust shall have the following responsibilities:
 1. Receiving, maintaining, and investing funds until final distribution of all Trust Funds.
 2. Reviewing certifications in accordance with the terms specified by this document.
 3. Reviewing reports on spending to ensure compliance with the Settlements.
 4. Disbursing the Annual Shares to the Commonwealth Account, County Abatement Account, and Litigating Subdivision Account for that year.
 5. Otherwise establishing its own operating rules and procedures.
 6. Preparing an annual report and accounting for the authorizing court which shall be made public and undertaking all other reporting requirements consistent with the terms of the Settlements.

VII. ALLOCATION

- A. The Trust Funds designated for the County Abatement Account shall be distributed directly to the Counties or such other organization designated by the County. Each County shall receive its share consistent with the methodology outlined in Exhibit 1 and as calculated separately with respect to each settlement, with each County receiving a minimum of \$1 million total combined from the Wave 1 Settlements, and a minimum of \$770,000 total combined from the Wave 2 Settlements. To the extent the Commonwealth receives less than the full amounts available under the Settlements, the Trustees shall reduce each County's share (identified in Exhibit 1) *pro rata*.
- B. The funds designated for the Litigating Subdivision Account shall be distributed directly to participating Litigating Subdivisions, as determined separately with respect to each settlement, based on population according to the 2020 Census, with the following caveats:
1. 25% of the Litigating Subdivision Account will be set aside for entities that have done substantial work to

advance litigation against the Wave 1 Settling Defendants and Teva and Allergan. In the case of the Wave 1 Settlements, the Teva Settlement Agreement, and the Allergan Settlement Agreement, those entities are Delaware County, Carbon County, and the City of Philadelphia.

2. Allocation for District Attorneys' shares will be based on half of the population of the County they serve.
3. Allocation of Litigating Special Districts' shares will be based on 10% of the population that they serve.
4. The following minimum payments will apply, subject to availability of funds:
 - a. For subdivisions with populations smaller than 10,000: \$80,000 from the Distributors Settlement Agreement, \$20,000 from the J&J Settlement Agreement, and \$72,000 from the Wave 2 Settlements.
 - b. For subdivisions with populations between 10,000 and 50,000: \$200,000 from the Distributors Settlement Agreement, \$50,000 from the J&J

Settlement Agreement, and \$180,000 from the Wave 2 Settlements.

- c. For subdivisions with populations between 50,001 and 100,000: \$400,000 from the Distributors Settlement Agreement, \$100,000 from the J&J Settlement Agreement, and \$360,000 from the Wave 2 Settlements.
- d. For subdivisions with populations larger than 100,000: \$800,000 from Distributors Settlement Agreement, \$200,000 from the J&J Settlement Agreement, and \$720,000 from the Wave 2 Settlements.

C. If Incentive A described in the Settlements is achieved, funds to be paid through the Litigating Subdivision Account will be paid out over the following three years' worth of payments.

D. If a District Attorney does not participate in one or more of these settlements, then the Trust Funds that would have been paid to such non-participating District Attorney out of that settlement (or those settlements) will be paid to those District Attorneys that agree to participate in that settlement (or those

settlements). The amount for a non-participating District Attorney being reallocated to participating District Attorneys shall be allocated in the same manner as funds are allocated in ¶VII(B)(2) above.

VIII. MISCELLANEOUS

- A. The Trust shall be dissolved upon final disbursement of all Trust Funds from all covered Settlements.
- B. The Trust shall not pay any Participating Subdivision in any year in which the Participating Subdivision fails to submit a certification by November 15 of the year in which the Trust has funds to distribute.
- C. The proceedings and meetings of this Trust shall be governed by the Sunshine Act, 65 Pa. C. S §§ 701-16.
- D. All Trustees and any person employed by the Trust shall be governed by and shall be considered Public Officials within the meaning of the Public Official and Employee Ethics Act, 65 Pa. C. S. §§ 1101-13 (“Ethics Act”) since such person will be either a Public Official or Public employee or appointed by Public Officials or appointed pursuant to this Order to perform a function administering a trust to protect the public interest. For

the avoidance of doubt, legal counsel, professional services providers, or any vendor that contracts with the Trust will not be considered a Public Official subject to the Ethics Act.

- E. This Court shall maintain jurisdiction over the Trust and the funds it holds until the Trust is dissolved.
- F. Any beneficiary of the Trust may petition the Court to allow spending on an item of abatement not contained in Exhibit E, provided such spending is deemed by the Court to reduce incidence or rate of opioid addiction and overdose deaths in the Commonwealth.
- G. Any beneficiary of the Trust may file a complaint with the Board of Trustees if the beneficiary disputes an action by the Trust with regard to that beneficiary, provided that such complaint is filed within 30 days of when the beneficiary knew or should have known of the basis for the complaint.
 - 1. Such complaint shall be in writing and the Board of Trustees must respond in writing to such beneficiary within 60 days of receipt of such complaint.

2. If the Board of Trustees' response does not resolve the beneficiary's complaint, the beneficiary may petition this Court for a resolution of its complaint.
3. No beneficiary shall have standing to challenge another beneficiary's use of Trust Funds under this Order or any action of the Trust with regard to another beneficiary.
4. Nothing in this Order shall change the requirements for SCAs under Federal or State laws.

IX. ATTORNEYS' FEES:

- A. The methodology for the payment of Attorneys' Fees and expenses for the Wave 1 Settlements is set forth in Exhibit 4.
- B. The methodology for the payment of Attorneys' Fees and expenses for the Wave 2 Settlements is set forth in Exhibit 8.

X. FORFEITURE, PENALTIES AND INCENTIVES.

- A. County Abatement Account Penalties and Incentives:
 1. Any County which agrees to participate in one or more of the settlements will receive 70% of the amount allocated to it under the Intrastate Allocation Formula ("Allocated

Share”) for each settlement in which it is participating.

For each such settlement, such County may receive up to an additional 30% of its allocated share by securing the participation of its constituent subdivisions as participants in the relevant settlement as follows:

- a. Any County where all the Litigating Subdivisions and all subdivisions with a population greater than 30,000 agree to participate in the relevant settlement will receive an additional 20% of its allocated share.
- b. Any County where all the Non-Litigating Subdivisions with a population greater than 10,000 agree to participate in the Wave 1 Settlements will receive an additional 10% of its allocated share.
- c. For the Wave 2 Settlements, any County that agrees to participate in a particular settlement will receive the additional 10% of its allocated share for that settlement.
- d. A subdivision which agrees to participate in either the Distributors Settlement Agreement or the J&J

Settlement Agreement, but not the other, the payment to the County shall have its allocation reduced by 150% of the pro-rata size of the settlement to which the subdivision did not agree.

- e. Funds withheld pursuant to Section X-Forfeitures, Penalties and Incentives will be re-allocated to the Commonwealth Account.
- f. For the avoidance of doubt, nothing in this section shall apply to or authorize any penalty for a Participating Subdivision's failure or inability to secure the participation of a District Attorney within its jurisdiction.

B. Litigating Subdivision Penalties

- 1. Any Litigating Subdivision that fails to agree to participate in a particular settlement shall receive no proceeds from that settlement from the County Abatement Account or the Litigating Subdivision Account and shall not have any portion of its Attorney Fees or Costs paid out of that settlement.

C. Inappropriate Spending and Failure to File Reports.

1. If a County or Litigating Subdivision spends some or all of its funds in a way that is not in accordance with the requirements of Exhibit E to the Settlements, fails to spend Trust Funds within the applicable deadline under ¶V(D)(10), or fails to timely provide the Board of Trustees with an annual or other report of its spending under ¶V(D)(11), the Board of Trustees may withhold the next year's payments to such County or Subdivision. The County or Litigating Subdivision will have up to 3 months from any applicable notice from the Board of Trustees to cure the deficiency. If the deficiency is not cured after 3 months from such notice, the Board of Trustees may reduce or withhold payments going forward, and re-allocate the difference to the Commonwealth Account.

So Ordered:

 10/15/2024
J.

Exhibit 1

County shares have been determined based on a 4-metric formula, with the following weights:

- **All Overdose Deaths** – Number of all overdose deaths 2015-2019 as compiled by the CDC (40%)
- **OUD-Related Hospitalizations** – Number of unique individuals hospitalized for any OUD-related diseases 2016-2019 as compiled by the Pennsylvania Health Care Cost Containment Council (PHC4) via OpenDataPA (20%)
- **EMS Naloxone Administrations** -- Number of naloxone doses administered by Emergency Medical Services 2018-2020 as compiled by the Pennsylvania Department of Health (20%)
- **Adjusted MME** - Total Morphine Milligram Equivalents (MME) of prescription opioids dispensed by county 2006-2014 per ARCOS data, adjusted by the ratio of OUD prevalence rate or the ratio of overdose deaths, whichever was higher per county (20%)

The resulting County shares are as follows:

County	4-Metric (MME Adjusted) Formula (unequal weights: (40-20-20-20)
Adams	0.344%
Allegheny	11.524%

Armstrong	0.606%
Beaver	1.274%
Bedford	0.192%
Berks	1.891%
Blair	0.807%
Bradford	0.225%
Bucks	5.803%
Butler	1.369%
Cambria	1.587%
Cameron	0.072%
Carbon	0.644%
Centre	0.250%
Chester	2.230%
Clarion	0.147%
Clearfield	0.299%
Clinton	0.105%
Columbia	0.328%
Crawford	0.671%
Cumberland	1.048%
Dauphin	1.611%
Delaware	6.468%
Elk	0.168%

Erie	2.051%
Fayette	1.348%
Forest	0.049%
Franklin	0.514%
Fulton	0.077%
Greene	0.205%
Huntingdon	0.179%
Indiana	0.683%
Jefferson	0.189%
Juniata	0.061%
Lackawanna	1.393%
Lancaster	2.266%
Lawrence	0.989%
Lebanon	0.603%
Lehigh	2.107%
Luzerne	3.282%
Lycoming	0.642%
McKean	0.180%
Mercer	0.931%
Mifflin	0.173%
Monroe	0.827%
Montgomery	5.047%

Montour	0.143%
Northampton	1.686%
Northumberland	0.578%
Perry	0.231%
Philadelphia	23.146%
Pike	0.283%
Potter	0.067%
Schuylkill	0.986%
Snyder	0.109%
Somerset	0.425%
Sullivan	0.050%
Susquehanna	0.166%
Tioga	0.149%
Union	0.082%
Venango	0.336%
Warren	0.139%
Washington	1.647%
Wayne	0.315%
Westmoreland	3.227%
Wyoming	0.204%
York	2.571%

Exhibit 2

[Year]

[County of _____][City of Philadelphia] Abatement Account
Certification

I, _____, on behalf of [the County of _____] [City of Philadelphia] hereby Certify that the County Abatement Funds received by [the County of _____] [the City of Philadelphia] will be used in a manner consistent with the Abatement uses described in Exhibit E of the Settlements and that the payee(s) and their addresses and the amount indicated are:

Payee:

Address:

Amount:

Date: County of _____

By: _____

Title: _____

[Date: City of Philadelphia

By: _____

Title: _____

Exhibit 3

[Year]

[County of _____][City of Philadelphia]Litigating Subdivision
Certification

I, _____, on behalf of [the County of _____] [City of Philadelphia] hereby certify that the Litigating Subdivision Funds received by [the County of _____] [the City of Philadelphia] will be used in a manner consistent with the Abatement uses described in Exhibit E of the Settlements and that the payee(s) and their addresses and the amount indicated are:

Payee:

Address:

Amount:

Date: County of _____

By: _____

Title: _____

[Date: City of Philadelphia

By: _____

Title: _____]

Exhibit 4

**IN THE COURT OF COMMON PLEAS OF
DELAWARE COUNTY, PENNSYLVANIA
CIVIL DIVISION**

DELAWARE COUNTY,
PENNSYLVANIA,

Plaintiff,

v.

PURDUE PHARMA L.P., et al.,

Defendants.

:
:
:
:
:
: COURT OF COMMON PLEAS
: DELAWARE COUNTY, PA
: CIVIL ACTION – LAW
:
:
: No. 2017-008095
:
:
:
:
:
:

**[PROPOSED] ORDER GRANTING PLAINTIFFS’ MOTION TO
ESTABLISH A PENNSYLVANIA OPIOID FEE FUND AND
APPOINT A SPECIAL MASTER TO DETERMINE AND DISBURSE
ATTORNEYS’ FEES AND ESTABLISH A PROCEDURE FOR
REIMBURSING COUNSEL FOR DOCUMENTED EXPENSES AND
COSTS**

AND NOW, this _____ day of April 2022, after review of the
Motion to Establish a Pennsylvania Opioid Fee Fund and Appoint a Special
Master to Determine and Disburse Fees and Establish a Procedure for
Reimbursing Counsel for Documented Expenses and Costs filed by Track 1
Plaintiffs Delaware County and Carbon County, Pennsylvania, it is hereby
ORDERED and **DECREED** as follows:

This Attorney Fee and Cost Order is entered into as an adjunct to the Pennsylvania Opioids Trust and Allocation Order entered in [INSERT CASE CAPTION] (the “Trust”) to which this is Exhibit 4. Attached as exhibits to this Order are the National Janssen Settlement Agreement (Exhibit A), and the National Distributor Settlement Agreement (Exhibit B) referred to as “Settlement Agreements” hereafter. Unless otherwise set forth herein, defined terms in this Order shall have the same meanings in the National J&J and Distributor Settlement Agreements and the Trust.

I. Establishment of Pennsylvania Opioid Fee Fund

Consistent with the terms of the Trust and pursuant to 42 P.S. § 2503(8), an attorney fee fund shall be established and held in a separate account subject to the jurisdiction of this Court, to be held and disbursed in a manner consistent with the terms of this Order (the “Pennsylvania Opioid Fee Fund”).

A. Amount and Timing of Payments to Establish the Fund

The amount of the Pennsylvania Opioid Fee Fund shall not exceed 6.6% of all base and incentive payments governmental entities will receive

in the Commonwealth of Pennsylvania over the course of all payment years under the J&J and Distributor Settlement Agreements.

With respect to the timing, although the payment terms from the Settling Defendants extend over an eighteen year period, if the Commonwealth of Pennsylvania is eligible for “Incentive A” under the J&J and Distributor Settlements, the Pennsylvania Opioid Fee Fund shall be funded in its entirety in the first three years, less any amounts required for suspensions, offsets or reductions pursuant to Sections IV, VII and XII of the Settlement Agreements. Under the following payment schedule: 50% paid in 2022; 25% paid in 2023; and 25% in paid in 2024.³ Alternatively, if the Commonwealth of Pennsylvania is not eligible for Incentive A, the Pennsylvania Opioid Fee Fund shall be funded in its entirety in the first five years, less any amount required for suspension, offsets and reductions provided for in the Settlement Agreements, with equal payments made in each settlement payment year, understanding that if Incentive A is not

³ For illustrative purposes only, if the Commonwealth will receive \$1,000,000,000 in payments from the settlements, with Incentive A, the Pennsylvania Opioid Fee Fund will receive \$66,000,000 total, with \$33,000,000 paid in payment year one, \$16,500,000 paid in payment year two, and \$16,500,000 paid in payment year three.

achieved, participation levels in the Commonwealth may increase in subsequent years, which may result in an increase in the overall funds to the Commonwealth and a corresponding increase of the Pennsylvania Opioid Fee Fund, causing some fluctuation in the amount of the payment each year such that each payment is not equal.⁴

Attorneys' fees and expenses awarded by the Special Master under Sections III, IV, and V of this Order shall be payable from the Pennsylvania Opioid Fee Fund upon award, notwithstanding the existence of any objections thereto, or potential for appeal therefrom, or collateral attack on the Trust or the Settlements or any part thereof. Any counsel who pursues an objection, appeal, or collateral attack on the Trust or the Settlements or any part thereof shall be ineligible for any attorneys' fees or expenses awarded by the Special Master until Sections III, IV, or V of this Order until such

⁴ For illustrative purposes only, if the Commonwealth will receive \$900,000,000 in payments from the settlements, without Incentive A, the Pennsylvania Opioid Fee Fund will receive \$59,400,000 total, with \$11,880,000 paid in payment year one, \$11,880,000 paid in payment year two, \$11,880,000 paid in payment year three, \$11,880,000 paid in payment year four, and \$11,880,000 paid in payment year five, but if participation levels increase, the payment amounts in payment years three to five may increase and not be equal.

objection, appeal, or collateral attack is resolved. Counsel shall only have standing to object to its own fee or cost award, and shall not have standing to object to a fee or cost award of any other counsel.

In addition, in the event an objection, appeal, or collateral attack is unsuccessful, any such counsel:

a) Must reimburse all fees and costs of the Special Master incurred in defending any award made under this Order;

b) Pay to Pennsylvania Opioid Fee Fund interest on the amount objected to at the rate of 5%;

c) Pay the fees of the Trust and the Pennsylvania Office of Attorney General incurred during the objection, appeal or collateral attack.

To ensure that payments to counsel do not exceed 6.6% of all base and incentive payments governmental entities will receive in the Commonwealth of Pennsylvania over the course of all payment years under the J&J and Distributor Settlement Agreements, in the event that any counsel appeals its own award of attorneys' fees or costs, the funds in dispute only shall be held in the Pennsylvania Opioid Fee Fund pending the appeal. If the appeal is resolved in favor of counsel who filed the appeal,

those funds, together with any interest, shall be payable immediately upon decision by the highest court to which the award was appealed, and the time to appeal or seek further review has expired. If the appeal is resolved against counsel who filed the appeal, the reserved funds, together with any interest, shall be distributed *pro rata* consistent with the Mathematical Formula for contingency fees described in Section IV.

As discussed in detail below, in order to be eligible to participate in the Pennsylvania Opioid Fee Fund, counsel must agree to waive enforcement of their fee contracts with respect to the Pennsylvania client(s) for whom they are seeking to recover fees. If the total population of the clients whose counsel do not agree to waive their fee agreements is between 10.01% to 25% of the total population of Participating Subdivisions (with the population of District Attorneys measured by half the population of the counties they serve), the amount of the Pennsylvania Opioid Fee Fund shall be reduced on a pro-rata basis, based on the percentage of the population of Participating Subdivisions represented by counsel who do not agree to waive their fee contracts.⁵ If counsel for 10% or fewer of Litigating Subdivisions

⁵ For illustrative purposes only, if the Pennsylvania Opioid Fee Fund is to be funded at \$66,000,000, but 15% of the eligible clients, by population, do not agree to waive their contracts and participate in the fund, then the

(measured by population of the clients for whom counsel is not participating) do not agree to waive their fee, the amount of the Pennsylvania Opioid Fee Fund shall not be reduced. If counsel for greater than 25% of Litigating Subdivisions (measured by participation of the clients for whom counsel is not participating) do not agree to waive their fee, there will be no further reductions to the amount of the fund beyond those that occur for greater than 10% up to 25%.

B. The Pennsylvania Opioid Fee Fund Shall Be a Qualified Settlement Fund

The Pennsylvania Opioid Fee Fund shall constitute a single qualified settlement fund within the meaning of section 468B of the Internal Revenue Code of 1986, as amended, and Treasury Regulation Sections 1.468B-1, *et seq.* and will be disbursed consistent with the terms of this order, and will remain subject to the continuing and exclusive jurisdiction of this Court. The

amount of the fund shall be reduced by \$9,900,000, for a total of \$56,100,000.

Fund will be an account where assets will be segregated from the general assets of the Defendant(s) and related persons or entities.

This Court has jurisdiction over this matter under Treas. Reg. § 1.468B-1(c)(1), which states in relevant part that a Qualified Settlement Fund “is established pursuant to an order of, or is approved by, the United States, any state (including the District of Columbia), territory, possession, or political subdivision thereof, or any agency or instrumentality (including a court of law) of any of the foregoing and is subject to the continuing jurisdiction of that governmental authority.”

No bond shall be required and all amounts deposited in the Pennsylvania Opioid Fee Fund shall be invested conservatively in a manner designed to assure timely availability of funds, protection of principal and avoidance of concentration risk. All payments into the Pennsylvania Opioid Fee Fund, and any interest thereon, will be held until disbursed in a manner consistent with this Order. No distributions shall be made from the Pennsylvania Opioid Fee Fund except through the process established by this Order. No parties or their counsel shall be considered to be in constructive receipt, as determined under federal income tax principles, of any amounts held by the Pennsylvania Opioid Fee Fund.

II. Appointment of Special Master and Administrator

The Court hereby appoints, retired Magistrate Judge Joel Schneider as Special Master, to oversee and allocate the Pennsylvania Opioid Fee Fund, and ARCHER Systems, LLC as Administrator to oversee administration and administrative costs of the Fund.

A. Special Master

Judge Schneider served as United States Magistrate Judge in the District of New Jersey for 14 years. During his tenure, he managed, settled, and decided thousands of cases in all aspects of civil litigation, including employment, civil rights, intellectual property, class/collective actions, products liability, contract, data breach, pharmaceutical, and other disputes. While on the bench, Judge Schneider developed a well-deserved reputation for effectively managing and settling complex and multi-party individual and class action cases, including three multidistrict litigations: Caterpillar Engine, Benicar and Valsartan. Specifically, Judge Schneider was recently appointed by the court to mediate the multi-billion dollar LTL/J&J bankruptcy litigation involving J&J's baby powder. He was

largely responsible for resolving the fairly recent \$350 million Benicar settlement (approximately 8000 claimants) and finalizing the attorneys' fee allocation. Judge Schneider also presently acts as the Special Master in the Johnson & Johnson MDL talc litigation (38,000 cases) and the coordinated talc (mesothelioma) cases pending in New Jersey state court. Judge Schneider is currently Of Counsel in the Alternative Dispute Resolution Practice Group at the law firm of Montgomery McCracken Walker & Rhoads LLP. Prior to his judicial appointment, he practiced in the tristate area for 26 years, where he specialized in complex civil litigation.

Judge Schneider was provided with a list of all Plaintiffs' counsel in these Coordinated Proceedings, and has advised he has no conflicts of interest with any of those counsel.

The Special Master shall be responsible for designing and implementing processes and procedures for the allocation of fees, costs, and expenses, consistent with the criteria set forth in this Order. To carry out these responsibilities, the Special Master may set deadlines for any submissions and hold hearings with all or any group of counsel without further consultation with the Court. The Special Master may also employ the services of assistants to act under his direction to accomplish the

objectives set forth in this Order. Subject to review by this Court under an abuse of discretion standard, the Special Master shall have the sole authority for making decisions regarding allocations, disbursements, and payments from the Pennsylvania Opioid Fee Fund.

The Special Master may communicate *ex parte* with counsel when such communication is necessary: (a) to maintain confidentiality or a privilege related to specific information; (b) to ensure the efficient administration and management and oversight of his responsibilities, including scheduling meetings, conferences, calls, or hearings; or (c) for other procedural, routine, or general non-substantive matters. Counsel shall not engage in *ex parte* communications with the Special Master regarding substantive matters.

The Special Master, and any assistant to whom he delegates any aspect of his responsibilities in this Order, including any third parties hired at the Special Master's direction, shall be immune from any liability resulting from any award made under this Order, or any action conducted pursuant to this Order as part of making any award. See *Binder v. Triangle Publications, Inc.*, 442 Pa. 319, 323, 275 A.2d 53, 56 (1971) (“All

communications pertinent to any stage of a judicial proceeding are accorded an absolute privilege which cannot be destroyed by abuse.”).

The services of the Special Master and any assistants to whom he delegates any part of his duties under this Order, the Administrator, and any vendors and services they determine to be necessary and appropriate to conduct and complete their work, shall be paid or reimbursed from the Pennsylvania Opioid Fee Fund. The Court has been advised that the Special Master will bill his time at \$800/hour.

As a threshold step in the fee allocation process, the Special Master shall allocate fifty percent (50%) of the Pennsylvania Opioid Fee Fund to be used exclusively for the payment of Agreed Litigation Conduct Fees, and the remaining fifty percent (50%) to be used for contingency fee awards.

B. Administrator

The Administrator shall assist the Special Master and shall be responsible for making any necessary tax filings and payments of taxes, estimated taxes, and associated interest and penalties, if any, by the Pennsylvania Opioid Fee Fund. The Administrator shall be responsible for responding to any questions from, or audits regarding such taxes by, the

Internal Revenue Service or any state or local tax authority, as well as questions from the Department of Labor. The Administrator shall also be responsible for complying with all tax information reporting and withholding requirements with respect to payments made by the Pennsylvania Opioid Fee Fund, as well as paying any associated interest and penalties. All such tax, interest, and penalty payments and all expenses and costs incurred in connection with taxation of the Pennsylvania Opioid Fee Fund (including, without limitation, expenses of tax attorneys and accountants) shall be paid from the Pennsylvania Opioid Fee Fund and shall be considered administrative costs. The Administrator will obtain a Federal Taxpayer Identification Number for the Fund upon entry of an order by this Court establishing the Fund. The Administrator shall be authorized, upon final distribution of all monies paid into the Fund to take appropriate steps to wind down the Fund and thereafter be discharged from any further responsibility with respect to the Fund.

The Administrator and/or its attorneys shall be indemnified and held harmless against reasonable expenses, costs and fees (including attorney fees), judgment, awards, and liabilities of all kinds incurred by the Administrator from any and all claims made by any person or entity that

attempts to assert a right of payment, reimbursement or garnishment against the Fund, except to the extent that it is finally determined by this Court that the Administrator and/or its attorneys was/were negligent or acted with willful misconduct in connection with the administration of this Fund.

The Administrator shall have the right to rely upon any affidavit, certificate, letter, notice, electronic mail or other document provided to the Administrator and in the Administrator's reasonable judgment believed to be genuine and sufficient. By way of example, this may include but is not limited to, wire instructions, IRS Form W-9, Plaintiffs' Counsel communications, payment instructions, fee deferment instructions, and the like.

The Court further appoints Huntington Bank as the custodian of the Fund who shall be responsible for any and all investment-related decisions, pursuant to the terms and conditions described in this Order.

III. Awards for Agreed Litigation Conduct Fees

With respect to the Agreed Litigation Conduct portion of the Pennsylvania Opioid Fee Fund, the Court hereby directs the Special Master to: (1) set up a process to receive requests for Agreed Litigation Conduct

fees and set forth the required materials to be provided to the Special Master in connection with fee requests; (2) make a preliminary recommendation on the distribution of Agreed Litigation Conduct fees; and (3) address any requests to be heard regarding that preliminary recommendation by attorneys that sought common-benefit fees and then, make a final determination regarding the distribution of Agreed Litigation Conduct fees to qualifying counsel. This Court may review the final determination of an approved distribution of any Agreed Litigation Conduct funds. Any review by this Court of an award made by the Special Master concerning the Agreed Litigation Conduct funds shall be under an abuse of discretion standard.

Counsel shall only be eligible to apply for Agreed Litigation Conduct fees concerning work incurred in connection with the representation of Pennsylvania clients who filed cases in the Unified Judicial System of Pennsylvania and executed Participation Agreements to participate in the J&J and Distributor Settlements. If counsel represents clients whose cases are pending in federal court in MDL 2804 or who do not participate in the J&J and Distributor Settlements, counsel may not be awarded Agreed Litigation Conduct fees for work incurred in connection with representation of those clients.

In making determinations for payments for Agreed Litigation Conduct fees, the Special Master shall give consideration to the factors set forth in *In re Baby Prod. Antitrust Litig.*, 708 F.3d 163, 176–77 (3d Cir. 2013) and *Maldonado v. Houstoun*, 256 F.3d 181, 187–88 (3d Cir. 2001).

As these have been applied and interpreted by courts with reference to Agreed Litigation Conduct and other court-awarded fees, as well as the following factors, which may be applied and given relative weight in the Special Master’s discretion:

- the applicant’s contemporaneously recorded time and labor dedicated to Pennsylvania Participating Subdivisions. Claimed “time” shall not be automatically accepted by the Special Master but shall be critically reviewed. Time and labor incurred by contract lawyers for document review shall not be included in connection with any applicant’s request for Agreed Litigation Conduct fees, but rather such time shall be submitted as an expense, for the actual cost of those services;
- the novelty, time, and complexity of the work performed for Pennsylvania Participating Subdivisions;

- the preclusion of other employment by the applicant due to time dedicated to Pennsylvania Participating Subdivisions;
- the “common benefit,” if any alleged to have been conferred by the applicant with respect to the coordinated proceedings pending before this Court;
- the amount of the expenditures paid by the applicant which were necessary to prosecute the applicant’s case(s);
- the experience, reputation, and ability of the applicant;
- the status of discovery in the cases primarily handled by the applicant in the coordinated proceedings pending before this Court;
- the nature of any work by the applicant on “bellwether” cases or cases that were similarly active in the coordinated proceedings pending before this Court;
- any pressure points successfully exerted by the applicant in cases against the Settling Defendants or any risk for Settling

Defendants created by the applicant in cases against them in the coordinated proceedings pending before this Court;

- any risk for defendants created by applicants in cases against the Settling Defendants in the coordinated proceedings pending before this Court;
- successful and unsuccessful motion practice in cases worked on by the applicant in the coordinated proceedings pending before this Court;
- the date of filing of any cases filed by the applicant in the coordinated proceedings pending before this Court;
- the number and population of entities represented by the applicant and the fees that would have been awarded under the extinguished contingent fee agreements with respect to the applicant's Pennsylvania Participating Subdivisions;
- whether the applicants' Pennsylvania Participating Subdivision clients brought claims against the Settling Defendants;

- whether the applicant has had a leadership role in the coordinated proceedings pending before this Court;
- whether the applicant has had a leadership role in any negotiations aimed at resolving the litigation in the coordinated proceedings pending before this Court; and
- any other factors that the Special Master finds to be appropriate to consider.

IV. Fee Awards Based on Contingent Fee Contracts

With respect to the contingent fee portion of the Pennsylvania Opioid Fee Fund, the Special Master is directed to establish and implement procedures for the distribution fees to compensate eligible counsel for work on behalf of Pennsylvania Participating Litigating Subdivisions, in lieu of enforcement of contingency fee contracts. As part of that process, counsel submitting fee petitions for each Participating Litigating Subdivision shall represent they waive enforcement rights against the subdivision clients of all contracts entered into in conjunction with the representation of Pennsylvania clients for whom they are seeking to recover contingency fees, prior to applying for contingency fees from the Pennsylvania Opioid Fee Fund.

With respect to contingency fee awards from the Pennsylvania Opioid Fee Fund, any counsel who represents Pennsylvania clients who executed Participation Agreements to participate in the J&J and Distributor Settlements shall be eligible to apply for contingency fees, regardless of the jurisdiction where they filed their cases, provided they comply with the other requirements in this Attorney Fee and Expense Order.

Awards of contingency fees shall be made by applying a mathematical model identical or substantially similar to the Mathematical Model attached as part of Exhibit R to the National Settlement Agreements (see Distributor Settlement Agreement at pp. R-22 to R-25 (the “Mathematical Model”) to the Pennsylvania Participating Subdivisions that are part of the coordinated proceedings pending before this Court. Awards of contingency fees made by the Special Master shall be based exclusively on (1) the settlement amount that will be received by each participating Pennsylvania Litigating Subdivision, the terms of each participating Pennsylvania Litigating Subdivision’s contingency fee contract, and the filing date for each participating Pennsylvania Litigating Subdivision. No other factors or subjective criteria may be used by the Special Master in calculating contingency fee awards. The Special Master is encouraged to work with

counsel who developed the above referenced the Mathematical Model. The Special Master shall oversee the application of the Mathematical Model and resolve any questions or disputes concerning eligibility. The Special Master is empowered to hear disputes concerning and ensure the accuracy of the mathematical calculation. As to awards from the Contingency Fee Fund, there shall be no right of appeal.

V. Reimbursement of Costs and Expenses

Consistent with the terms of the Trust, counsel shall be reimbursed for documented costs and expenses incurred in connection with the representation of Pennsylvania clients who filed cases in the Unified Judicial System of Pennsylvania and whose clients executed Participation Agreements to participate in the J&J and Distributor Settlements.

Requests for costs and expenses from the Pennsylvania Opioid Fee Fund shall be submitted in two parts, which counsel must segregate in their applications. The first part shall be for all costs and expenses incurred in connection with the representation of Pennsylvania clients who filed cases in the Unified Judicial System of Pennsylvania and executed Participation Agreements to participate in the J&J and Distributor Settlements, except for

costs for document review by contract attorneys. Before submitting requests for costs and for these types of costs, counsel must first apply to the cost fund established in connection with the Distributor and J&J Settlements in the MDL. However, because the MDL cost fund may not make awards in time for the Special Master to take into account those awards in these proceedings, counsel may elect to submit a request for cost and expenses from the Pennsylvania Opioid Fee Fund while a request to the MDL cost fund remains pending. If counsel make this election, counsel shall certify that they will (1) report all amounts subsequently received from the MDL cost fund incurred in their representation of Pennsylvania clients who filed cases in the Unified Judicial System of Pennsylvania; and (2) immediately reimburse the Pennsylvania Opioid Fee Fund in any amount awarded by the MDL cost fund for expenses incurred in the representation of Pennsylvania clients who filed cases in the Unified Judicial System of Pennsylvania, plus accrued interest at the same net rate as is earned by the Pennsylvania Opioid Fee Fund. Counsel shall be reimbursed for these costs within a reasonably prompt time following the receipt of a request from counsel that complies with this Order.

The second part of counsel's request shall be for costs for document review by contract attorneys incurred in connection with the representation of Pennsylvania clients who filed cases in the Unified Judicial System of Pennsylvania and executed Participation Agreements to participate in the J&J and Distributor Settlements. Counsel are not required to apply to the cost fund established in connection with the Distributor and J&J Settlements in the MDL before submitting requests for these types of costs. Once counsel submits a request that complies with this Order, these costs shall be reimbursed in 2022.

To the extent that counsel are not fully reimbursed by the MDL Cost Fund for costs and expenses incurred the representation of Pennsylvania clients who filed cases in the Unified Judicial System of Pennsylvania and executed Participation Agreements to participate in the J&J and Distributor Settlements, counsel shall be reimbursed for such costs and expenses from the Pennsylvania Opioid Fee Fund.

To the extent the Special Master requires assistance to further the purpose of this Order, the Special Master is authorized to retain and utilize, under his supervision, accountants and/or other professionals and vendors, as

necessary and appropriate, to assist in the administration and distribution of expenses.

VI. Miscellaneous

To prevent insolvency of the Pennsylvania Opioid Fee Fund, no award shall be made until all applications have been received and award amounts for each applicant are finalized.

SO ORDERED, this _____ day of _____,
2022.

BY THE COURT:

Hon. Barry C. Dozor

Exhibit 5

The participating subdivisions are identified below:

1. Abington Township, Montgomery County
2. Adams County
3. Adams Township, Butler County
4. Aliquippa City, Beaver County
5. Allegheny County
6. Allentown City, Lehigh County
7. Altoona City, Blair County
8. Amity Township, Berks County
9. Antrim Township, Franklin County
10. Armstrong County
11. Aston Township, Delaware County
12. Beaver County
13. Bedford County
14. Bensalem Township, Bucks County
15. Berks County
16. Berwick Borough, Columbia County
17. Bethel Park Municipality, Allegheny County
18. Bethlehem City, Lehigh County, Northampton County
19. Bethlehem Township, Northampton County
20. Blair County
21. Bloomsburg Town, Columbia County
22. Bradford County
23. Bristol Township, Bucks County
24. Buckingham Township, Bucks County
25. Bucks County
26. Butler City, Butler County
27. Butler County
28. Butler Township, Butler County
29. Caln Township, Chester County
30. Cambria County
31. Cameron County

32. Carbon County
33. Carlisle Borough, Cumberland County
34. Cecil Township, Washington County
35. Center Township, Beaver County
36. Centre County
37. Chambersburg Borough, Franklin County
38. Cheltenham Township, Montgomery County
39. Chester City, Delaware County
40. Chester County
41. Chestnuthill Township, Monroe County
42. Clarion County
43. Clearfield County
44. Clinton County
45. Coal Township, Northumberland County
46. Coatesville City, Chester County
47. College Township, Centre County
48. Columbia Borough, Lancaster County
49. Columbia County
50. Concord Township, Delaware County
51. Coolbaugh Township, Monroe County
52. Cranberry Township, Butler County
53. Crawford County
54. Cumberland County
55. Cumru Township, Berks County
56. Darby Borough, Delaware County
57. Dauphin County
58. Delaware County
59. Derry Township, Dauphin County
60. Derry Township, Westmoreland County
61. Dingman Township, Pike County
62. District Attorney Of Berks County
63. District Attorney Of Bucks County
64. District Attorney Of Chester County
65. District Attorney Of Clearfield County

66. District Attorney Of Dauphin County
67. District Attorney Of Delaware County
68. District Attorney Of Erie County
69. District Attorney Of Northampton County
70. District Attorney Of Westmoreland County
71. Douglass Township, Montgomery County
72. Dover Township, York County
73. Doylestown Township, Bucks County
74. Dunmore Borough, Lackawanna County
75. East Bradford Township, Chester County
76. East Cocalico Township, Lancaster County
77. East Goshen Township, Chester County
78. East Hempfield Township, Lancaster County
79. East Lampeter Township, Lancaster County
80. East Norriton Township, Montgomery County
81. East Pennsboro Township, Cumberland County
82. East Stroudsburg Borough, Monroe County
83. East Whiteland Township, Chester County
84. Easton City, Northampton County
85. Easttown Township, Chester County
86. Edwardsville Borough, Luzerne County
87. Elizabeth Township, Allegheny County
88. Elizabethtown Borough, Lancaster County
89. Elk County
90. Emmaus Borough, Lehigh County
91. Ephrata Borough, Lancaster County
92. Ephrata Township, Lancaster County
93. Erie City, Erie County
94. Erie County
95. Exeter Borough, Luzerne County
96. Exeter Township, Berks County
97. Fairview Township, Erie County
98. Fairview Township, Luzerne County
99. Fairview Township, York County

100. Falls Township, Bucks County
101. Fayette County
102. Ferguson Township, Centre County
103. Forest County
104. Forks Township, Northampton County
105. Forty Fort Borough, Luzerne County
106. Franconia Township, Montgomery County
107. Franklin County
108. Franklin Park Borough, Allegheny County
109. Fulton County
110. Greene County
111. Greene Township, Franklin County
112. Greensburg City, Westmoreland County
113. Guilford Township, Franklin County
114. Hamilton Township, Franklin County
115. Hampden Township, Cumberland County
116. Hanover Borough, York County
117. Hanover Township, Luzerne County
118. Hanover Township, Northampton County
119. Harborcreek Township, Erie County
120. Harrisburg City, Dauphin County
121. Hatfield Township, Montgomery County
122. Haverford Township, Delaware County
123. Hazleton City, Luzerne County
124. Hempfield Township, Westmoreland County
125. Hermitage City, Mercer County
126. Hilltown Township, Bucks County
127. Hopewell Township, Beaver County
128. Horsham Township, Montgomery County
129. Huntingdon County
130. Indiana Borough
131. Indiana County
132. Jefferson County
133. Jefferson Hills Borough, Allegheny County

134. Johnstown City, Cambria County
135. Juniata County
136. Kingston Borough, Luzerne County
137. Lackawanna County
138. Lancaster City, Lancaster County
139. Lancaster County
140. Lancaster Township, Lancaster County
141. Lansdale Borough, Montgomery County
142. Lansdowne Borough, Delaware County
143. Lawrence County
144. Lebanon City, Lebanon County
145. Lebanon County
146. Lehigh Township, Northampton County
147. Lehman Township, Pike County
148. Limerick Township, Montgomery County
149. Lock Haven City, Clinton County
150. Logan Township, Blair County
151. Lower Allen Township, Cumberland County
152. Lower Burrell City, Westmoreland County
153. Lower Macungie Township, Lehigh County
154. Lower Makefield Township, Bucks County
155. Lower Merion Township, Montgomery County
156. Lower Moreland Township, Montgomery County
157. Lower Paxton Township, Dauphin County
158. Lower Pottsgrove Township, Montgomery County
159. Lower Providence Township, Montgomery County
160. Lower Saucon Township, Northampton County
161. Lower Southampton Township, Bucks County
162. Loyalsock Township, Lycoming County
163. Luzerne County
164. Lycoming County
165. Mahoning Township, Carbon County
166. Manchester Township, York County
167. Manheim Township, Lancaster County

168. Manor Township, Lancaster County
169. Marple Township, Delaware County
170. Mccandless Township, Allegheny County
171. Mckean County
172. Mercer County
173. Middle Smithfield Township, Monroe County
174. Middletown Township, Bucks County
175. Middletown Township, Delaware County
176. Mifflin County
177. Milford Township, Bucks County
178. Millcreek Township, Erie County
179. Monroe County
180. Montgomery County
181. Montgomery Township, Montgomery County
182. Montour County
183. Morrisville Borough, Bucks County
184. Mount Joy Township, Lancaster County
185. Mount Lebanon Township, Allegheny County
186. Mount Pleasant Township, Westmoreland County
187. Muhlenberg Township, Berks County
188. Munhall Borough, Allegheny County
189. Murrysville Municipality, Westmoreland County
190. Nanticoke City, Luzerne County
191. Nether Providence Township, Delaware County
192. New Britain Township, Bucks County
193. New Castle City, Lawrence County
194. New Garden Township, Chester County
195. New Kensington City, Westmoreland County
196. Newberry Township, York County
197. Newtown Township, Bucks County
198. Newtown Township, Delaware County
199. Norristown Borough, Montgomery County
200. North Huntingdon Township, Westmoreland County
201. North Lebanon Township, Lebanon County

202. North Middleton Township, Cumberland County
203. North Strabane Township, Washington County
204. North Union Township, Fayette County
205. North Versailles Township, Allegheny County
206. North Whitehall Township, Lehigh County
207. Northampton County
208. Northampton Township, Bucks County
209. Northumberland County
210. Palmer Township, Northampton County
211. Patton Township, Centre County
212. Penn Hills Township, Allegheny County
213. Penn Township, Lancaster County
214. Penn Township, Westmoreland County
215. Penn Township, York County
216. Perry County
217. Peters Township, Washington County
218. Philadelphia City, Philadelphia
219. Philadelphia School District, Philadelphia County
220. Phoenixville Borough, Chester County
221. Pike County
222. Pine Township, Allegheny County
223. Pittsburgh City, Allegheny County
224. Plains Township, Luzerne County
225. Plumstead Township, Bucks County
226. Plymouth Township, Montgomery County
227. Pocono Township, Monroe County
228. Potter County
229. Pottstown Borough, Montgomery County
230. Pottsville City, Schuylkill County
231. Radnor Township, Delaware County
232. Rapho Township, Lancaster County
233. Reading City, Berks County
234. Richland Township, Bucks County
235. Richland Township, Cambria County

236. Ridley Township, Delaware County
237. Robinson Township, Allegheny County
238. Ross Township, Allegheny County
239. Rostraver Township, Westmoreland County
240. Salisbury Township, Lancaster County
241. Salisbury Township, Lehigh County
242. Sandy Township, Clearfield County
243. Schuylkill County
244. Scranton City, Lackawanna County
245. Sharon City, Mercer County
246. Silver Spring Township, Cumberland County
247. Snyder County
248. Somerset County
249. Somerset Township, Somerset County
250. South Lebanon Township, Lebanon County
251. South Middleton Township, Cumberland County
252. South Union Township, Fayette County
253. South Whitehall Township, Lehigh County
254. Southeastern Pennsylvania Transportation Authority,
255. Spring Garden Township, York County
256. Spring Township, Berks County
257. Springettsbury Township, York County
258. Springfield Township, Delaware County
259. Springfield Township, Montgomery County
260. St. Marys City, Elk County
261. State College Borough, Centre County
262. Stroud Township, Monroe County
263. Sugar Notch Borough, Luzerne County
264. Sullivan County, Sullivan County
265. Susquehanna County
266. Susquehanna Township, Dauphin County
267. Swatara Township, Dauphin County
268. Tioga County, Tioga County
269. Towamencin Township, Montgomery County

270. Tredyffrin Township, Chester County
271. Union County, Union County
272. Union Township, Lawrence County
273. Unity Township, Westmoreland County
274. Upper Allen Township, Cumberland County
275. Upper Chichester Township, Delaware County
276. Upper Darby Township, Delaware County
277. Upper Dublin Township, Montgomery County
278. Upper Gwynedd Township, Montgomery County
279. Upper Macungie Township, Lehigh County
280. Upper Merion Township, Montgomery County
281. Upper Moreland Township, Montgomery County
282. Upper Providence Township, Delaware County
283. Upper Providence Township, Montgomery County
284. Upper Southampton Township, Bucks County
285. Upper St Clair Township, Allegheny County
286. Upper Uwchlan Township, Chester County
287. Uwchlan Township, Chester County
288. Venango County
289. Wampum Borough, Lawrence County
290. Warminster Township, Bucks County
291. Warren County
292. Warrington Township, Bucks County
293. Warwick Township, Bucks County
294. Warwick Township, Lancaster County
295. Washington City, Washington County
296. Washington County
297. Washington Township, Franklin County
298. Wayne County
299. Waynesboro Borough, Franklin County
300. West Bradford Township, Chester County
301. West Chester Borough, Chester County
302. West Goshen Township, Chester County
303. West Hanover Township, Dauphin County

304. West Hempfield Township, Lancaster County
305. West Lampeter Township, Lancaster County
306. West Manchester Township, York County
307. West Mifflin Borough, Allegheny County
308. West Norriton Township, Montgomery County
309. West Pittston Borough, Luzerne County
310. West Whiteland Township, Chester County
311. Westmoreland County
312. Westtown Township, Chester County
313. White Township, Indiana County
314. Whitehall Borough, Allegheny County
315. Whitehall Township, Lehigh County
316. Whitmarsh Township, Montgomery County
317. Whitpain Township, Montgomery County
318. Wilkes Barre Township, Luzerne County
319. Wilkes-Barre City, Luzerne County
320. Williamsport City, Lycoming County
321. Willistown Township, Chester County
322. Windsor Township, York County
323. Worcester Township, Montgomery County
324. Wright Township, Luzerne County
325. Wyoming Borough, Luzerne County
326. Wyoming County
327. Wyomissing Borough, Berks County
328. Yeadon Borough, Delaware County
329. York City, York County
330. York County
331. York Township, York County

EXHIBIT 6

The participating subdivisions in Wave 2 are identified below:

1. Abington Township, Montgomery County
2. Adams County
3. Adams Township, Butler County
4. Aliquippa City, Beaver County
5. Allegheny County
6. Allentown City, Lehigh County
7. Altoona City, Blair County
8. Amity Township, Berks County
9. Antrim Township, Franklin County
10. Armstrong County
11. Aston Township, Delaware County
12. Baldwin Borough, Allegheny County
13. Beaver County
14. Bedford County
15. Bensalem Township, Bucks County
16. Berks County
17. Berwick Borough, Columbia County
18. Bethel Park Municipality, Allegheny County
19. Bethlehem City, Lehigh County/Northampton County
20. Bethlehem Township, Northampton County
21. Blair County
22. Bradford County
23. Bristol Township, Bucks County
24. Bucks County
25. Butler City, Butler County
26. Butler County
27. Butler Township, Butler County
28. Caln Township, Chester County
29. Cambria County
30. Cameron County
31. Carbon County

32. Carlisle Borough, Cumberland County
33. Cecil Township, Washington County
34. Center Township, Beaver County
35. Centre County
36. Chambersburg Borough, Franklin County
37. Cheltenham Township, Montgomery County
38. Chester City, Delaware County
39. Chester County
40. Chestnuthill Township, Monroe County
41. Clarion County
42. Clearfield County
43. Clinton County
44. Coal Township, Northumberland County
45. Coatesville City, Chester County
46. Columbia Borough, Lancaster County
47. Columbia County
48. Concord Township, Delaware County
49. Coolbaugh Township, Monroe County
50. Cranberry Township, Butler County
51. Crawford County
52. Cumberland County
53. Cumru Township, Berks County
54. Darby Borough, Delaware County
55. Dauphin County
56. Delaware County
57. Derry Township, Dauphin County
58. Derry Township, Westmoreland County
59. Dingman Township, Pike County
60. District Attorney Of Beaver County*
61. District Attorney Of Berks County
62. District Attorney Of Bucks County

* Only participating in the settlements with Walgreens, CVS, and Walmart

63. District Attorney Of Butler County*
64. District Attorney Of Chester County
65. District Attorney Of Clearfield County
66. District Attorney Of Dauphin County
67. District Attorney Of Delaware County
68. District Attorney Of Erie County
69. District Attorney Of Lawrence County*
70. District Attorney Of Lehigh County
71. District Attorney Of Northampton County
72. District Attorney Of Philadelphia†
73. District Attorney Of Westmoreland County
74. District Attorney Of Wyoming County
75. Douglass Township, Montgomery County
76. Doylestown Township, Bucks County
77. Dunmore Borough, Lackawanna County
78. East Cocalico Township, Lancaster County
79. East Goshen Township, Chester County
80. East Hempfield Township, Lancaster County
81. East Lampeter Township, Lancaster County
82. East Norriton Township, Montgomery County
83. East Stroudsburg Borough, Monroe County
84. East Whiteland Township, Chester County
85. Easton City, Northampton County
86. Easttown Township, Chester County
87. Edwardsville Borough, Luzerne County
88. Elizabeth Township, Allegheny County
89. Elizabethtown Borough, Lancaster County
90. Elk County
91. Emmaus Borough, Lehigh County
92. Ephrata Borough, Lancaster County
93. Ephrata Township, Lancaster County
94. Erie City, Erie County

* Only participating in the settlements with Walgreens, CVS, and Walmart

† Only participating in the settlements with Teva, Allergan, and Walmart

95. Erie County
96. Exeter Borough, Luzerne County
97. Exeter Township, Berks County
98. Fairview Township, Erie County
99. Fairview Township, Luzerne County
100. Falls Township, Bucks County
101. Fawn Township, York County
102. Fayette County
103. Forest County
104. Forks Township, Northampton County
105. Forty Fort Borough, Luzerne County
106. Franklin County
107. Franklin Park Borough, Allegheny County
108. Fulton County
109. Greene County
110. Greene Township, Franklin County
111. Greensburg City, Westmoreland County
112. Guilford Township, Franklin County
113. Hamilton Township, Franklin County
114. Hampden Township, Cumberland County
115. Hampton Township, Allegheny County
116. Hanover Borough, York County
117. Hanover Township, Luzerne County
118. Hanover Township, Northampton County
119. Harrisburg City, Dauphin County
120. Harrison Township, Allegheny County
121. Hatfield Township, Montgomery County
122. Haverford Township, Delaware County
123. Hazleton City, Luzerne County
124. Hempfield Township, Westmoreland County
125. Hermitage City, Mercer County
126. Hopewell Township, Beaver County
127. Horsham Township, Montgomery County
128. Huntingdon County

129. Indiana County
130. Jefferson County
131. Jefferson Hills Borough, Allegheny County
132. Johnstown City, Cambria County
133. Juniata County
134. Kingston Borough, Luzerne County
135. Lackawanna County
136. Lancaster City, Lancaster County
137. Lancaster County
138. Lancaster Township, Lancaster County
139. Lansdale Borough, Montgomery County
140. Lansdowne Borough, Delaware County
141. Lawrence County
142. Lebanon City, Lebanon County
143. Lebanon County
144. Lehigh County
145. Lehigh Township, Northampton County
146. Lehman Township, Pike County
147. Limerick Township, Montgomery County
148. Lock Haven City, Clinton County
149. Logan Township, Blair County
150. Lower Allen Township, Cumberland County
151. Lower Burrell City, Westmoreland County
152. Lower Gwynedd Township, Montgomery County
153. Lower Macungie Township, Lehigh County
154. Lower Makefield Township, Bucks County
155. Lower Merion Township, Montgomery County
156. Lower Moreland Township, Montgomery County
157. Lower Paxton Township, Dauphin County
158. Lower Pottsgrove Township, Montgomery County
159. Lower Providence Township, Montgomery County
160. Lower Salford Township, Montgomery County
161. Lower Saucon Township, Northampton County
162. Lower Southampton Township, Bucks County

163. Luzerne County
164. Lycoming County
165. Mahoning Township, Carbon County
166. Mahoning Township, Lawrence County
167. Manchester Township, York County
168. Manheim Township, Lancaster County
169. Manor Township, Lancaster County
170. Marple Township, Delaware County
171. Mccandless Township, Allegheny County
172. Mckean County
173. Mckeesport City, Allegheny County
174. Mercer County
175. Middle Smithfield Township, Monroe County
176. Middletown Township, Bucks County
177. Middletown Township, Delaware County
178. Mifflin County
179. Millcreek Township, Erie County
180. Monroe County
181. Monroeville Municipality, Allegheny County
182. Montgomery County
183. Montgomery Township, Montgomery County
184. Montour County
185. Moon Township, Allegheny County
186. Morrisville Borough, Bucks County
187. Mount Joy Township, Lancaster County
188. Mount Lebanon Township, Allegheny County
189. Mount Pleasant Township, Westmoreland County
190. Muhlenberg Township, Berks County
191. Munhall Borough, Allegheny County
192. Murrysville Municipality, Westmoreland County
193. Nanticoke City, Luzerne County
194. Nether Providence Township, Delaware County
195. New Britain Township, Bucks County
196. New Castle City, Lawrence County

197. New Garden Township, Chester County
198. New Hanover Township, Montgomery County
199. New Kensington City, Westmoreland County
200. Newberry Township, York County
201. Newtown Township, Bucks County
202. Newtown Township, Delaware County
203. Norristown Borough, Montgomery County
204. North Fayette Township, Allegheny County
205. North Huntingdon Township, Westmoreland County
206. North Lebanon Township, Lebanon County
207. North Strabane Township, Washington County
208. North Union Township, Fayette County
209. North Versailles Township, Allegheny County
210. Northampton County
211. Northampton Township, Bucks County
212. Northumberland County
213. Palmer Township, Northampton County
214. Patton Township, Centre County
215. Penn Hills Township, Allegheny County
216. Penn Township, Westmoreland County
217. Penn Township, Lancaster County
218. Perry County
219. Peters Township, Washington County
220. Philadelphia County-Philadelphia City[†]
221. Phoenixville Borough, Chester County
222. Pike County
223. Pine Township, Allegheny County
224. Pittsburgh City, Allegheny County
225. Plains Township, Luzerne County
226. Plymouth Township, Montgomery County
227. Pocono Township, Monroe County
228. Potter County

[†] Only participating in the settlements with Teva, Allergan, and Walmart

229. Pottstown Borough, Montgomery County
230. Pottsville City, Schuylkill County
231. Radnor Township, Delaware County
232. Rapho Township, Lancaster County
233. Reading City, Berks County
234. Richland Township, Allegheny County
235. Richland Township, Bucks County
236. Richland Township, Cambria County
237. Ridley Township, Delaware County
238. Robinson Township, Allegheny County
239. Ross Township, Allegheny County
240. Rostraver Township, Westmoreland County
241. Salisbury Township, Lancaster County
242. Salisbury Township, Lehigh County
243. Sandy Township, Clearfield County
244. Schuylkill County
245. Scranton City, Lackawanna County
246. Shaler Township, Allegheny County
247. Sharon City, Mercer County
248. Silver Spring Township, Cumberland County
249. Skippack Township, Montgomery County
250. Snyder County
251. Somerset County
252. Somerset Township, Somerset County
253. South Lebanon Township, Lebanon County
254. South Union Township, Fayette County
255. Southeastern Pennsylvania Transportation Authority
256. Spring Township, Berks County
257. Springettsbury Township, York County
258. Springfield Township, Delaware County
259. Springfield Township, Montgomery County
260. St. Marys City, Elk County
261. State College Borough, Centre County
262. Stroud Township, Monroe County

263. Sugar Notch Borough, Luzerne County
264. Sullivan County
265. Susquehanna County
266. Susquehanna Township, Dauphin County
267. Swatara Township, Dauphin County
268. Tioga County
269. Union County
270. Union Township, Lawrence County
271. Unity Township, Westmoreland County
272. Upper Allen Township, Cumberland County
273. Upper Chichester Township, Delaware County
274. Upper Darby Township, Delaware County
275. Upper Dublin Township, Montgomery County
276. Upper Gwynedd Township, Montgomery County
277. Upper Macungie Township, Lehigh County
278. Upper Merion Township, Montgomery County
279. Upper Moreland Township, Montgomery County
280. Upper Providence Township, Delaware County
281. Upper Providence Township, Montgomery County
282. Upper Southampton Township, Bucks County
283. Upper St Clair Township, Allegheny County
284. Uwchlan Township, Chester County
285. Venango County
286. Wampum Borough, Lawrence County
287. Warminster Township, Bucks County
288. Warren County
289. Warrington Township, Bucks County
290. Warwick Township, Bucks County
291. Warwick Township, Lancaster County
292. Washington City, Washington County
293. Washington County
294. Washington Township, Franklin County
295. Wayne County
296. Waynesboro Borough, Franklin County

297. West Chester Borough, Chester County
298. West Goshen Township, Chester County
299. West Hanover Township, Dauphin County
300. West Hempfield Township, Lancaster County
301. West Lampeter Township, Lancaster County
302. West Manchester Township, York County
303. West Mifflin Borough, Allegheny County
304. West Norriton Township, Montgomery County
305. West Pittston Borough, Luzerne County
306. Westmoreland County
307. Westtown Township, Chester County
308. White Township, Indiana County
309. Whitehall Borough, Allegheny County
310. Whitmarsh Township, Montgomery County
311. Whitpain Township, Montgomery County
312. Wilkes Barre Township, Luzerne County
313. Wilkes-Barre City, Luzerne County
314. Wilkesburg Borough, Allegheny County
315. Williamsport City, Lycoming County
316. Willistown Township, Chester County
317. Windsor Township, York County
318. Worcester Township, Montgomery County
319. Wright Township, Luzerne County
320. Wyoming Borough, Luzerne County
321. Wyoming County
322. Wyomissing Borough, Berks County
323. Yeadon Borough, Delaware County
324. York City, York County
325. York County
326. York Township, York County

Exhibit 7

For purposes of the Allergan Settlement, any County, County Subdivision, or District Attorney that had existing litigation against Teva, but did not have litigation against Allergan, will not receive a share of the Litigation Fund for the Allergan settlement. Those subdivisions will receive an Allergan Allocation Adjustment as defined in Paragraph III.I. of the Trust Order.

The following Participating Subdivisions had litigation against Teva, and will receive an Allergan Allocation Adjustment:

1. Allegheny County
2. Clearfield County
3. Dauphin County
4. Erie County
5. Pike County
6. City of Pittsburgh
7. Schuylkill County
8. Tioga County

The Allergan Allocation Adjustment will equal an extra \$1,000,000 from the following sources: \$500,000 from the Pennsylvania Opioid Fee Fund and \$500,000 from the Commonwealth's Additional Remediation. The eight subdivisions listed above would have received \$1,512,796.16 if they had sued Allergan, but instead will receive \$1,000,000 using the Allergan Allocation Adjustment. Assuming Pennsylvania receives the maximum under the Allergan settlement, the 8 subdivisions listed above will receive:

Subdivision	Allergan Modified Allocation
Allegheny County	\$ 513,017.07
Clearfield County	\$ 33,048.46
Dauphin County	\$ 117,488.56
Erie County	\$ 111,119.83
Pike County	\$ 25,520.34
Pittsburgh city	\$ 124,285.97
Schuylkill County	\$ 58,682.13
Tioga County	\$ 16,837.64

Exhibit 8

**IN THE COURT OF COMMON PLEAS OF
DELAWARE COUNTY, PENNSYLVANIA
CIVIL DIVISION**

DELAWARE COUNTY, PENNSYLVANIA,	:	
	:	
Plaintiff,	:	COURT OF COMMON PLEAS
	:	DELAWARE COUNTY, PA
v.	:	CIVIL ACTION – LAW
	:	
PURDUE PHARMA L.P., et al.,	:	No. 2017-008095
	:	
Defendants.	:	
	:	
	:	

**[PROPOSED] ORDER GRANTING PLAINTIFFS’ MOTION TO
ADD FUNDS TO THE PENNSYLVANIA OPIOID FEE FUND**

AND NOW, this _____ day of _____ 2024, after review of the
Motion to Add Funds to the Pennsylvania Opioid Fee Fund filed by Track 1
Plaintiffs Delaware County and Carbon County, Pennsylvania, it is hereby
ORDERED and **DECREED** as follows:

This Order adding funds to the Pennsylvania Opioid Fee Fund is entered into as an adjunct to the Pennsylvania Opioids Trust and Allocation Order entered in 244 M.D. 2022 and 243 M.D. 2022 (the “Trust”) to which this is Exhibit 8. Attached as exhibits to this Order are the National Teva Settlement Agreement (Exhibit C), the National Allergan Settlement Agreement (Exhibit D), the National Walgreens Settlement Agreement (Exhibit E), the National CVS Settlement Agreement (Exhibit F), and the National Walmart Settlement Agreement (Exhibit G) referred to as “Wave 2 Settlement Agreements” hereafter. Unless otherwise set forth herein, defined terms in this Order shall have the same meanings in the Wave 2 Settlement Agreements, the Trust, and this Court’s Order establishing the Pennsylvania Opioid Fee Fund on August 2, 2022.

I. Wave 2 Attorney Fees and Costs to be Disbursed by the Pennsylvania Opioid Fee Fund

Consistent with the terms of the Trust and pursuant to 42 P.S. § 2503(8), the Wave 2 Settlement attorney fees and costs will be disbursed by the Pennsylvania Opioid Fee Fund established by Order of this Court on August 2, 2022.

A. Amount and Timing of Payments to the Fund

Regarding the Wave 2 Settlements, the Pennsylvania Opioid Fee Fund shall not exceed the following percentages of all base and incentive payments the governmental entities will receive in the Commonwealth of Pennsylvania over the course of all payment years: 2.18% for Teva, 2.97% for Allergan, 0.7% for Walgreens, 1.26% for CVS, and 1.38% for Walmart.

With respect to the timing, although the payment terms from the Wave 2 Settlement Agreements vary up to a fifteen year period, if the Commonwealth of Pennsylvania is eligible for “Incentive A” under the Wave 2 Settlements, the Pennsylvania Opioid Fee Fund shall receive full payment from the Wave 2 Settlements in the first three years, less any amounts required for suspensions, offsets or reductions pursuant to Sections VI and X of the Teva Settlement Agreement, Sections VI and IX of the Allergan Settlement Agreement, Sections IV, VII and XI of the Walgreens and Walmart Settlement Agreements, and Sections IV, VII, and XII of the CVS Settlement Agreement. Under the following payment schedule: 50% paid in 2024; 25% paid in 2025; and 25% in paid in 2026.⁶ Alternatively, if

⁶ For illustrative purposes only, if the Commonwealth will receive \$1,000,000,000 in payments from the settlements, with Incentive A, the

the Commonwealth of Pennsylvania is not eligible for Incentive A, the Pennsylvania Opioid Fee Fund shall receive full payment from the Wave 2 Settlements in the first five years, less any amount required for suspension, offsets and reductions provided for in the Wave 2 Settlement Agreements, with equal payments made in each settlement payment year, understanding that if Incentive A is not achieved, participation levels in the Commonwealth may increase in subsequent years, which may result in an increase in the overall funds to the Commonwealth and a corresponding increase of the Pennsylvania Opioid Fee Fund, causing some fluctuation in the amount of the payment each year such that each payment is not equal.⁷

Pennsylvania Opioid Fee Fund will receive \$66,000,000 total, with \$33,000,000 paid in payment year one, \$16,500,000 paid in payment year two, and \$16,500,000 paid in payment year three.

⁷ For illustrative purposes only, if the Commonwealth will receive \$900,000,000 in payments from the settlements, without Incentive A, the Pennsylvania Opioid Fee Fund will receive \$59,400,000 total, with \$11,880,000 paid in payment year one, \$11,880,000 paid in payment year two, \$11,880,000 paid in payment year three, \$11,880,000 paid in payment year four, and \$11,880,000 paid in payment year five, but if participation levels increase, the payment amounts in payment years three to five may increase and not be equal.

B. Methodology for the Disbursement of the Wave 2 Settlement

Attorney Fees and Costs

The Wave 2 Settlement Attorney Fees and Costs shall follow the methodology for disbursement outlined in this Court’s August 2, 2022, Order creating the Pennsylvania Opioid Fee Fund. The Sections relating to the collateral attacks, the Special Master, the Administrator, Awards for Agreed Litigation Conduct Fees, Fee Awards Based on Contingent Fee Contracts, and Reimbursement of Costs and Expenses are all applicable to the Wave 2 Settlement Attorney Fees and Costs.

II. Miscellaneous

To prevent insolvency of the Pennsylvania Opioid Fee Fund, no award shall be made until all applications have been received and award amounts for each applicant are finalized.

SO ORDERED, this ____ day of _____,
2024.

BY THE COURT:

Hon. Barry C. Dozor